A Pilot Study to Determine the Effectiveness of Probiotic Use in Elderly Patients with Antibiotic-Associated Diarrhea by Peate, Jenna L
University of Nebraska - Lincoln 
DigitalCommons@University of Nebraska - Lincoln 
Nutrition & Health Sciences Dissertations & 
Theses Nutrition and Health Sciences, Department of 
Summer 7-7-2010 
A Pilot Study to Determine the Effectiveness of Probiotic Use in 
Elderly Patients with Antibiotic-Associated Diarrhea 
Jenna L. Peate 
University of Nebraska at Lincoln, jenna.peate@huskers.unl.edu 
Follow this and additional works at: https://digitalcommons.unl.edu/nutritiondiss 
 Part of the Dietetics and Clinical Nutrition Commons 
Peate, Jenna L., "A Pilot Study to Determine the Effectiveness of Probiotic Use in Elderly Patients with 
Antibiotic-Associated Diarrhea" (2010). Nutrition & Health Sciences Dissertations & Theses. 9. 
https://digitalcommons.unl.edu/nutritiondiss/9 
This Article is brought to you for free and open access by the Nutrition and Health Sciences, Department of at 
DigitalCommons@University of Nebraska - Lincoln. It has been accepted for inclusion in Nutrition & Health Sciences 
Dissertations & Theses by an authorized administrator of DigitalCommons@University of Nebraska - Lincoln. 
 
 
 
A Pilot Study to Determine the Effectiveness of Probiotic Use in Elderly Patients with 
Antibiotic-Associated Diarrhea 
 
By 
 
   Jenna Peate 
 
 
A THESIS 
 
 
Presented to the Faculty of 
The Graduate College at the University of Nebraska 
In Partial Fulfillment of Requirements 
For the Degree of Master of Science 
 
Major: Nutrition and Health Sciences 
 
Under the Supervision of Professors Kaye Stanek-Krogstrand and Julie A. Albrecht  
 
 
Lincoln, Nebraska 
 
July, 2010 
 
 
 
 
 A Pilot Study to Determine the Effectiveness of Probiotic Use in Elderly Patients with 
Antibiotic-Associated Diarrhea 
Jenna Peate 
University of Nebraska, 2010 
 
Advisors:  Kaye Stanek Krogstrand and Julie Albrecht 
 Long-term care settings have the majority of their patients on multiple antibiotics, 
and outbreaks of antibiotic-associated diarrhea and Clostridium difficile are common.  
Probiotics have been used with these patients to reduce these side effects.  Probiotics can 
re-establish the composition of intestinal microflora, enhance immune response, and clear 
pathogens from the host which may reduce the symptoms of antibiotic-associated 
diarrhea.  Therefore, the goal of this study was to conduct a retrospective study of the 
effectiveness of using probiotic in  elderly patients in a long-term care facility in a 
Midwestern city who suffered  from antibiotic-associated diarrhea.  The probiotic, 
CulturelleTM had been administered once a day to eight males and twelve female patients 
who were taking antibiotics and stool consistency and number were recorded.  Out of the 
original group, seven of the patients receiving the probiotic appeared to have positive 
effects while two patients had negative effects on stools.  Thirteen patients showed no 
change in stool consistency and number.  It was difficult to determine the effects of the 
probiotic due to the use by the facility of a bowel movement protocol for preventing 
constipation and impaction, and the lack of dietary records. 
 Published studies in patients in long-term facilities vary greatly in terms of trial 
design, type and dose of probiotic and duration of treatment, which may explain why 
probiotics work for some patients and not for others.  Probiotic use is becoming more 
 accepted with antibiotic-associated diarrhea but due to the lack of definitive evidence 
about efficacy and the safety of probiotic use, more studies need to be conducted.  
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Chapter I.  Introduction 
 Long-term care settings have the majority of their patients on multiple antibiotics 
and outbreaks of antibiotic-associated diarrhea and Clostidium difficile are common.  
Probiotics have been used with antibiotic use to reduce or possibly prevent these side 
effects (Hamilton-Miller, 2004; Isolauri, 2001; McFarland, 2006).  Published studies for 
patients in long-term care facilities vary greatly in terms of trial design, type and dose of 
probiotic and duration of treatment which may explain why probiotics appear to work for 
some patients and not for others.   
 The most susceptible group for antibiotic-associated diarrhea in the hospital 
appears to be the elderly (Hamilton-Miller, 2004). Elderly people may be regarded as 
immunocompromised due to their decrease in their ability to fight infections as they age.  
That is one reason why researchers develop strategies that can boost immunity in the 
elderly (Hamilton-Miller, 2004).  Gill et al. (2001) reported the beneficial effects of the 
administration of L rhamnosus for three weeks in elderly subjects.  These beneficial 
effects were:  decrease in irregular stools and decrease in irregular consistency.  
Improvements in symptoms were shown in subjects over 70 years old and who had 
immunity issues prior to treatment with the probiotic.   
It is known that probiotics can re-establish the composition of the intestinal 
microflora, enhance immune response, and clear pathogens from the host; all of which 
may reduce the symptoms of antibiotic-associated diarrhea. The use of probiotics is 
expanding to treat antibiotic-associated diarrhea and becoming more accepted.  However, 
there is a lack of strong evidence about the efficacy and safety of probiotic use.  Because 
of this situation, more studies need to be conducted (McFarland, 2006). 
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 The goal of the present study was to retrospectively examine the effectiveness of 
using a probiotic in institutionalized elderly patients in a long-term care facility in a 
Midwestern city who had received antibiotics and had antibiotic-associated diarrhea 
and/or Clostidium difficile. 
Chapter II. Literature Review 
The word, probiotic, LVDVVRFLDWHGZLWKWKH*UHHNWHUPWKDWPHDQV³IRUOLIH´5HLG
(2003) defined probiotic as live microorganisms administered in adequate amounts, 
which has beneficial physiological effects on the host. Many credit the Russian 
researcher, Dr. Elie Metchnikoff, for the development of probiotics (Reid, 2005).  Brown 
(2004) states that a probiotic is a nonpathogenic organism, such as yeast or bacteria, in 
IRRGVWKDWFDQH[HUWDSRVLWLYHLQIOXHQFHRQWKHKRVW¶VKHDOWK7KHWKHRU\EHKLQG
probiotics is that live microorganisms in food or supplements improve microbial balance 
of the intestinal tract.   
The use of probiotics has been reported to be effective in the elderly population 
suffering from antibiotic-associated diarrhea and some who have Clostridium difficile 
(Hamilton-Miller, 2004; Isolauri, 2001).  Probiotics are strains of bacteria that are 
naturally occurring in our intestinal tract.  Different probiotic strains have been studied in 
the clinical setting and have been used to treat and/or prevent certain diseases (Hamilton-
Miller, 2004; Isolauri 2001).  The concept of probiotic use has advanced rapidly over the 
last several years.  A bacterium or product containing bacteria is not considered a 
probiotic unless the bacteria are viable at the time of use in sufficient quantity to confer a 
physiologic health benefit.  The intentional modification of the intestinal microbiota with 
probiotics leads to select clinical beneficial effects, such as reduction of diarrhea.  Such 
3 
 
specific effects with ingestion of particular strains have been demonstrated (BioDrugs, 
1999).  Table 1 provides an example of the probiotic bacterial strains and when they are 
used (Douglas and Sanders, 2008). 
Table 1.  List of Bacterial and Yeast Strains Used as Probiotics 
Indication Genus, species, strain 
(commercial strain 
designation) 
Products (format) 
Infant diarrhea L. rhamnous GG (LGG) 
 
 
L. Casei DN114001 
(Immunitas) 
CulturelleTM (capsule)  
DanimalsTM (drinkable 
yogurt) 
 
DanActiveTM (fermented 
milk) 
Inflammatory bowel 
conditions (primary 
evidence in pouchitis) 
8 strain combination of 3 
Bifidobacterium strains, 4 
Lactobacillus strains and S. 
thermophilus 
VSL#3TM (powder) 
Antibiotic associated 
diarrhea; C. difficile 
S. cerevisiae (S. boulardii) 
 
 
L. rhamnosus GG 
 
 
L. casei DN114001 
 
L. acidophilus CL 1285 plus 
L. casei 
FlorastorTM (powder) 
LalflorTM (capsule) 
 
CulturelleTM (capsule) 
DanimalsTM (drinkable 
yogurt) 
 
DanActiveTM (fermented 
milk) 
 
BioK+CL1285TM 
(fermented milk, capsule) 
Gut transit time B. animalis DN137 010 
(Bifidus regularis) 
ActiviaTM (yogurt) 
Keeping healthy L. reuteri ATCC 55730 
 
 
 
 
L. casei DN114001 
BioGala Chewable Gut 
Health TabletsTM, BioGala 
Gut Health Probiotic 
StrawsTM 
 
DanActiveTM (fermented 
milk) 
Atopic dermatitis (primary 
evidence is prevention 
when fed to newborn 
infants) 
L. rhamnosus GG CulturelleTM (capsule) 
DanimalsTM (drinkable 
yogurt) 
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Lactose intolerance Most strains L. bulgaricus 
and/or S. thermophilus 
All yogurts with live, active 
cultures 
Colic in Infants L. reuteri ATCC 55730 
(Protectis) 
Reuteri drops 
Immune support B lactis HN019 (HOWARU 
or DR10) 
 
 
B lactis Bb-12 
 
 
L casei DN 14001 
Strain sold as an ingredient 
for dairy and supplement 
products 
 
Good Start Natural 
CulturesTM (infant formula) 
 
DanActiveTM (fermented 
milk) 
Vaginal applications L rhamnosus GR-1 plus L 
reuteri RC-14 
Fern-DophilusTM (capsules) 
Irritable bowel syndrome 
symptoms 
B infantis 35264 (Bifantis) AlignTM (capsules) 
Douglas, 2008. 
 Lactobacillus bacterial strains are typically used for non-pathogenic infections 
and some opportunistic infections.  Lactobacillus strains are normally found in the small 
intestine.  Of more than 100 Lactobacillus bacterial species, the following are commonly 
used probiotics: L. acidophilus, L. casei, L. rhamnosus, and L. fermentum.  Most of the 
time, Streptococcus bacterial strains are not used as a health benefit.  However, there is 
one strain that has been shown to be helpful: Streptococcus thermophilus.  Enterococcus 
bacterial strains are typically used for infections due to opportunistic pathogens.  
Bifidobactrium bacterial strains are typically used for non-pathogenic infections and 
some isolated cases of human infection.  They are strictly anaerobic and normally found 
in the large intestine.  There are over 30 Bifidobactrium bacterial strains; some common 
strains are: B. bifidum, B. adolescentis, B. animalis, and B. therophilum.  Spores of a 
number of Bacillus bacterial strains are used as probiotics and are often classified as soil-
based probiotics.  Some examples of the Bacillus species are: Bacillus cereus, B. subtilis, 
and B. coagulans.  Saccharomyces yeast strains are typically used for non-pathogenic 
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infections and some isolated cases of human infection.  Of the Saccharomyces yeast 
species the S. boulardii is the only one used as a probiotic.  This yeast strain seems to be 
unaffected by gastric acid and bile.  It has been used alone and in combination with other 
bacterial strains to be effective with Clostridium difficile and diarrhea (Olmstead et al., 
2008).   
Dependence of the intestinal microbes in the food makes it possible to take 
measures to modify intestinal microflora and to replace the harmful microbes with good 
microbes (Culligan et al., 2009). Companies develop and market probiotics as a 
functional food.  When a person ingests ELOOLRQVRI³JRRG´EDFWHULD, which are normally 
found in a healthy gut, they may improve the immune system (Marteau et al., 2001). 
Probiotics can help stabilize the gut microbial environment and the intestinal barrier, 
enhance systemic responses, and mucosal IgA (antibody responsible for mucosal 
immunity) responses, thus promoting the formation of the immunologic barrier in the gut 
mucosa.  It has been shown that probiotic consumption increases specific intestinal 
microflora, but does not usually increase the total bacteria in the intestinal tract (Brown, 
2004).  Probiotics were reported to reduce pathogens found in the gut due to nonspecific 
host resistance (Salminen et al, 1998).  Marteau and associates (2001) believes that 
through modulation of the endogenous ecosystem or the immune system, the probiotics 
can influence the intestinal physiology.  Brown (2004) suggested that studies have shown 
that to see a positive effect, large quantities of probiotics must be consumed.   Probiotic 
benefits are based on survival of the bacteria or yeast strains in the gastrointestinal tract, 
as well as overall health.  Some variables that affect the benefits of probiotics are: the 
strain, storage conditions, chemical additives, and other interactions (Brown, 2004). 
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It has been suggested that disruption of the balance in the gastrointestinal tract can 
contribute to diarrhea and other gastrointestinal side effects (Brown, 2004). When 
patients are placed on antibiotics, a common side effect is diarrhea.  This is thought to be 
caused either by increasing gastrointestinal motility or by disturbing the normal flora of 
the colon (Kyne, Farrell and Kelly, 2001).  Another hypothesis is that antibiotic-
associated diarrhea may be the result of overgrowth of toxigenic Clostridium difficile in 
the intestinal tract.  Clostridium difficile is a spore-forming, gram-positive anaerobic 
bacteria that produces two toxins.  Clostridium difficile is commonly associated with 
patients in hospitals as well as long-term care facilities. Diseases that result from 
Clostridium difficile infections include: sepsis, perforations of the colon, toxic 
megacolon, pseudomembranous colitis, and sometimes death (CDC, 2004). Symptoms of 
Clostridium difficile usually include: watery diarrhea, fever, loss of appetite, nausea, and 
abdominal pain (CDC, 2004). Patients that are at an increased risk for Clostridium 
difficile include those who have antibiotic exposure, gastrointestinal surgery, 
immunocompromised conditions, and long term stays in healthcare settings (CDC, 2004). 
Clostridium difficile is transmitted through the feces, which can be passed to patients by 
healthcare workers who do not follow safety and sanitation rules.  In 23% of patients, 
Clostridium difficile associated disease will resolve within two to three days of 
discontinuing the antibiotic to which the patient was previously exposed.  The infection is 
usually treated with ten days of antibiotic use, such as metronidazole or vancomycin 
(CDC, 2004). 
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Diarrhea 
Diarrhea is defined as an increase in frequency of bowel movements and/or an 
increase in water content of stools that affects either the consistency or the volume of 
fecal output.  Other definitions describe diarrhea as the abnormality in stool production as 
greater than 200 g/day for adults, and greater than 20 g/kg for children (Donowitz et al.; 
Kokke and Saidi, 1995). The etiology of the diarrhea can also serve as a framework for 
discussion and understanding of diarrheal conditions.  Diarrhea can be classified in 
different ways.  First, diarrhea can be either acute or chronic. Acute diarrhea is 
considered short-term, whereas chronic diarrhea can last several weeks.  Chronic diarrhea 
is usually associated with electrolyte imbalances, malabsorption, dehydration, and 
malnutrition (McFarland, 2006).  Second, diarrhea can also be classified as either 
secretory diarrhea or osmotic diarrhea.  Secretory diarrhea is when there is an increased 
amount of active secretion, therefore, an inhibition of absorption occurs.  Usually there is 
not structural damage to the intestinal tract.  Osmotic diarrhea occurs when too much 
water is drawn to the bowels, which can be the result of malabsorption.  Antibiotic-
associated diarrhea (AAD) and Clostridium difficile disease (CDD) are common 
conditions linked to the use of antibiotics (Culligan et al., 2009).  In antibiotic-associated 
diarrhea, diarrhea occurs in less than or equal to 20% of patients who receive antibiotics 
(McFarland, 2006).  Antibiotic-associated diarrhea results from a microbial imbalance 
that leads to a decrease in gut microflora, which, in turn, is responsible for colonization 
resistance and to a decrease in the fermentation capacity of the colon.  Studies evaluating 
the efficacy of probiotics for the treatment of these two conditions (AAD and CDD) have 
had mixed results (McFarland 2006). McFarland (2006), defined diarrhea as ORRVH
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VWRROVZLWKLQKRXUVIRUGD\VRUORRVHVWRROVZLWKLQhours.  Antibiotic-
associated diarrhea was defined as diarrhea within 2 months of exposure to antibiotics.  
Clostridium difficile disease was defined as diarrhea associated with a positive 
Clostridium difficile culture or toxin within a month of exposure to antibiotics 
(McFarland, 2006).   
The Elderly Population 
The most susceptible group for antibiotic-associated diarrhea in the hospital 
appears to be the elderly (Hamilton-Miller, 2004). Elderly people may be regarded as 
immunocompromised due to their decrease in their ability to fight infections as they age.  
That is one reason why researchers develop strategies that can boost immunity in the 
elderly (Hamilton-Miller, 2004).  Gill et al. (2001) reported the beneficial effects of the 
administration of L rhamnosus for three weeks in elderly subjects.  These beneficial 
effects are decrease in irregular stools and decrease in irregular consistency.  
Improvements in symptoms were shown in subjects over 70 years old and who had 
immunity issues prior to treatment with the probiotic.  Van de Water et al. (1999) found 
that yogurt consumption for one year decreased the incidence of allergies and 
inflammatory markers in a group of healthy elderly subjects.  There are three common 
problems in the elderly population: malnutrition, constipation, and a decreased ability to 
fight infections. Probiotics may have a beneficial effect on all of these problems.  Further 
research is necessary to determine long term outcomes and the most suitable probiotic 
strains to administer to the elderly (Hamilton-Miller, 2004).   
Only one trial has been conducted specifically in elderly subjects, and no benefit 
from taking S. boulardii was reported.  This study had a major limitation; the dose of 226 
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mg S. boulardii daily waVORZ'¶6RX]D, 2002).  Other studies have reported positive 
effects with a daily dose of 1 g S. boulardii.  A meta-analysis of nine trials concluded that 
probiotics may be useful in treating antibiotic induced diarrhea but further trials are 
needed with the elderly populatiRQ'¶6RX]D et al., 2002). 
McFarland 2006 conducted a meta-analysis of 31 randomized controlled trials.  
The meta-analysis revealed that probiotics had a significant protective effect against the 
development of antibiotic-associated diarrhea. This study also revealed that the probiotic 
strains that were found effective with antibiotic-associated diarrhea were S. boulardii, L. 
rhamnosus GG, and a mixture of two strains of Lactobacilli.  No adverse events were 
reported for a majority of the trials and those that did reported minor adverse events 
including thirst and constipation (McFarland, 2006).  The clinical and economic costs of 
antibiotic-associated diarrhea are significant and better treatments are needed.  Probiotics 
may offer potential effective therapy for antibiotic-associated diarrhea by restoring 
intestinal microbial balance. 
The Gastrointestinal Tract 
The gastrointestinal tract provides a protective barrier between the internal 
environment and microorganisms in the external environment.  The first line of host 
defense is directed toward the elimination of foreign antigens that have penetrated the 
mucosa, and the regulation of immune responses (Isolauri, 2001).  As a result, the 
gastrointestinal barrier controls antigen transport and the generation of immunologic 
properties in the gut (Ducroc et al., 1983). The mucosal surface of the gut prevents a 
large amount of pathogens, toxins, and allergens from entering through this barrier. 
However, the mucosal surface also has to allow nutrients to enter.  The intestinal flora 
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actively interacts with this mucosal surface.  The gut is considered the largest lymphoid 
organ in the body.  The gut associated lymphoid tissue (GALT) evolves and responds to 
the presence of and changes in the intestinal flora.  Lack of WKLV³PLFURELDOH[SHULHQFH´
leads to significant pathophysiological consequences.  One example would be an 
underdeveloped GALT in animals without effective intestinal flora results in persistent 
enteritis, severe infections, and poor survival.  An effective and metabolically active 
intestinal flora is critical for the maintenance of a healthy gut epithelium, vitamin 
production, and bile acid metabolism.  Additionally changes in the human microflora 
have been correlated with modulated local and systemic immune responses of the GALT 
(BioDrugs, 1999).  Adult intestinal microflora contains approximately 500 different 
bacterial strains.  The strains with health-promoting properties principally include 
bifidobacteria and lactobacilli.  When inflammation or infection occurs, the microfloral 
balance of the gut is altered in such a way that the numbers of potentially pathogenic 
bacteria grow, and the healthy interaction between the host and microbe is disturbed so 
that an immune response may be induced by resident bacteria (Salminen et al., 1998). 
CulturelleTM 
A published study demonstrated that the co-administration of antibiotics and 
CulturelleTM (Lactobacillus GG) in children significantly reduced the incidence of 
antibiotic-associated diarrhea.  A placebo or CulturelleTM (Lactobacillus GG) was given 
to 200 children at the same time antibiotic therapy was started (Vanderhoof, 1999).  The 
parents were questioned by telephone, every three days, about the number and 
consistency of stools and about numerous other gastrointestinal symptoms.  Only patients 
assigned to a 10 day course of antibiotic therapy were considered for this study.  
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Probiotics were given throughout the course of antibiotic therapy.  Older children were 
given 2 capsules per day of CulturelleTM (Lactobacillus GG) and children who weighed 
less than 12 kg were given only 1 capsule per day.  The incidence of diarrheal stools was 
24% in the placebo group compared with 7% in the probiotic treatment group.  Usually 
diarrhea is one reason why children must stop antibiotic treatment.  The diarrhea can also 
lead to inability to be in a daycare setting which means parents must miss work.  
CulturelleTM (Lactobacillus GG) was discovered in 1985 at Tufts University in 
Boston, Massachusetts by Dr. Sherwood H. Gorbach and Dr. Barry R. Goldin (Amerifit 
Brand, 2010).   CutlurelleTM is promoted as the premiere probiotic in the world.  
CulturelleTM consists of Lactobacillus GGTM (10 billion cells), microcrystalline cellulose, 
gelatin, and milk proteins. The producers of CulturelleTM attempted to make their product 
at the highest purity and potency for consumers at the time of use.  They achieve this by 
guaranteeing that CulturelleTM contains at least 10 billion live cells per capsule at the time 
of use.  To maintain freshness, each of the capsules are individually double-foil-protected 
and packed in such a way to keep light, moisture, heat and air out to assure stability and 
maximum potency (Amerifit Brand, 2010).  Keeping CulturelleTM in a refrigerator or 
freezer will increase its shelf life but is not required. The CulturelleTM company promotes 
their probiotic as an all-natural dietary supplement that improves digestion and creates a 
stronger immune system.  They recommend taking one capsule per day to strengthen the 
immune system while promoting digestive health (Amerifit Brand, 2010).  Along with a 
balanced diet rich in fiber, vitamins and minerals, a probiotic supplement like 
CulturelleTM can strengthen the immune system and boost your immune response 
(Amerifit Brand, 2010). 
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Probiotic use is becoming more accepted with antibiotic-associated diarrhea but 
due to the lack of definitive evidence about efficacy and the safety of probiotic use in the 
elderly population.  More controlled studies are needed in the area of elderly patients 
suffering from antibiotic-associated diarrhea and the effectiveness of probiotics. Thus, a 
retrospective case study in a long-term care facility using the probiotic, CulturelleTM, in 
the elderly population who are suffering from antibiotic-associated diarrhea in a long 
term care setting is needed. 
Objectives 
The objectives of this study were: 
To determine changes in bowel patterns in patients who suffer from antibiotic 
induced diarrhea (at least 14 days of data prior to implementation of probiotic) and during 
the probiotic use; and 
To qualitatively compare bowel records (consistency and frequency) before and 
after the probiotic use. 
Chapter III. Materials and Methods 
The present study was conducted as a retrospective case study to examine the 
stool scores and the use of probiotics with patients suffering from antibiotic-associated 
diarrhea.  After approval by the University of Nebraska-Lincoln Institutional Review 
Board, the review of patient records at a long-term care facility in a Midwestern city 
began.  This long-term care facility includes home health care, hospice, home delivered 
meals, adult day services, and elder living options.  Originally, the researcher reviewed 
patients who were inpatient residents at the care facility. Specifically, the criterion was 
narrowed to those patients who had suffered from infections between March 2007 and 
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March 2009 and who were given an antibiotic and the probiotic, CulturelleTM 
(Lactobacillus GG).  Using Vista KeeneTM , a program that this care facility uses to keep 
their medical records, the census, registration, physician orders, and care plans were 
examined.  The census indicated when the patient had been admitted and discharged from 
the long-term care facility and where they went when discharged.  The registration 
included the personal history, allergies, age, sex, and race of the patients.  The physician 
orders were a key area to narrow the search for appropriate patients to include in the case 
study.  It was the location for all medication orders, lab tests, appointments, diet orders, 
antibiotic orders, and probiotic orders.  The last area examined was the care plan section 
of Vista KeeneTM.  It provided information on the disease states and the care plan that 
was set forth by the dietitians and doctors. 
The long-term care facility uses a program called Live Care TrackerTM to 
document bowel records and stool scores for patients.  Each patient record was examined 
individually, and the search was narrowed based on the census, antibiotic 
implementation, and probiotic use.  After narrowing the search of patients to those who 
met our criteria, a list of each bowel movement per day was listed.  If the patient did not 
KDYHDERZHOPRYHPHQWLWMXVWVDLG³1R´+RZHYHULIWKH\KDGDERZHOPRYHPHQWLW
was scored as to size, consistency, and whether they were continent.  Each time a patient 
had a bowel movement, it was scored in this manner. 
The purpose of the bowel movement plan or protocol is to ensure regularity and 
prevention of impaction.  At the facility, each patient is assessed to determine if he/she 
has regular bowel movements.  If not, a plan for bowel care was initiated in a timely 
manner ensuring that the client remains free of constipation and impaction.  The 
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procedure starts with resident assistants documenting patients¶ bowel movements each 
shift for their assigned client and recording it in Care TrackerTM.  Next, the staff observes 
cognitively impaired patients for behaviors that could indicate the need to evacuate 
bowels, such as restlessness, digging in the rectum, and agitation.  These behaviors were 
reported to the charge nurse for follow up.  Next, the evening shift nurse or medication 
DLGHUXQVD³ERZHOPRYHPHQWSURWRFROFURVVWDE´Ueport in Care TrackerTM to identify the 
total number of days each patient has not had a bowel movement.  Also, if the patient 
does not have bowel care orders or a problem has been identified, the charge nurse will 
notify the physician of the patients¶ bowel status and request an order for use of facility 
bowel care protocol or other orders to manage patients¶ bowels as per physician order.  
The bowel care protocol starts at 4 pm on day three of no bowel movement at which time, 
30 ml Milk of MagnesiaTM is given.  At 4 pm on day four of no bowel movement, 10 mg 
Suppository R Bisacodyl (DulcolaxTM) is given.  If no stool occurs within 4 hours of 
having DulcolaxTM, the patient is re-evaluated to rule out impaction and administered one 
of the following: Enema R of Sodium Phosphate (fleets) or 4oz Magnesium Citrate.  If no 
results, the physician is updated on the patients¶ bowel status, at which time a request for 
routine bowel medication may be made.  The nurse will update the care plan and inform 
the staff of the pUREOHPQHHGUHJDUGLQJWKHSDWLHQWV¶ bowel movement and the 
interventions for those patients who require bowel care programs.  The nurse will follow 
up to ensure that the patients¶ bowel care plan was effective.  The patients¶ nutrition and 
hydration status is assessed on admission and on an ongoing basis by the Food and 
Nutrition Department of the facility. 
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After data were collected from Live Care TrackerTM, the researcher created a graph 
for each selected patient to compare the number of stools per day.  It was color coded to 
show the consistency, which was the most important part of the stool score.  If the stool 
was soft, then orange was the designated color.  If the stool was formed, green was 
designated.  If the stool was hard, then a dark blue was designated.  Lastly, if the stool 
was loose or diarrhea in consistency, then red was the designated color.  The antibiotics, 
probiotics, bowel plan, and dates were placed on the graph.  Graphing the stool scores 
helped identify the number of stools a patient had and then in combination with the color 
scale, the consistency.  This graphing system helped identify days where symptoms were 
exacerbated or days that patients¶ stools were more normalized.  The antibiotics, 
probiotics, and bowel plan were placed on the graph in an attempt to determine the 
effectiveness of the probiotic. 
From the established criteria, approximately 500 medical records could be used 
and it was determined this was too large of a patient group to examine for this qualitative 
study.  Too many variables were not controlled to conduct a quantitative study.  The 
study focus was then narrowed to 20 patient records to be used as case studies.  The 
selection criteria was to have the bowel movement data from patients who were on an 
antibiotic at least 14 days of data prior to implementation of probiotic, on an antibiotic 
while on the probiotic, and then data after the antibiotic was stopped.    
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Chapter IV. Results & Discussion 
Both males and females were included, race did not play a part in selection, 
however, all 20 patient recorded were those of Caucasian race.  There were eight males 
and twelve females in our study.   
Case Study One 
A white male, born on March 9, 1920, was admitted to the long-term care facility 
on November 23, 2004 and discharged December 22, 2004.  He was readmitted on May 
16, 2007 and discharged on July 18, 2007.  He was readmitted on July 27, 2007 until 
March 20, 2008.  
Bowel Movement Protocol 
Case Study One was placed on the bowel movement protocol on November 24, 
2004 to December 22, 2004.  The movement bowel protocol was restarted on May 29, 
2007 to July 17, 2007.  Again the bowel movement protocol was started on July 31, 2007 
to March 20, 2008.   
Probiotic Plan  
Case Study One was administered one capsule per day of the probiotic, 
CulturelleTM on August 31, 2007 with no stop date set.  He was then re-administered one 
capsule of the probiotic, CulturelleTM, per day starting on December 27, 2007 with no 
stop date. 
Antibiotic Plan 
Case Study One was started on 500 mg LevaquinTM once a day for an unknown 
infection on November 23, 2004 until November 28, 2004.  He was also started on 250 
mg FlagylTM once a day for an unknown infection on November 23, 2004 until 
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November 28, 2004.  He was started on 500 mg LevaquinTM once a day for a fever on 
August 16, 2007 until August 27, 2007.  He was started on 750 mg LevaquinTM once a 
day for upper respiratory infection on October 22, 2007 until October 27, 2007. He was 
started on 750 mg LevaquinTM once a day for pneumonia on December 3, 2007 until 
December 8, 2007.  He was started on 500 mg AzithromycinTM once a day for upper 
respiratory infection on December 12, 2007 until December 13, 2007.  He was started on 
250 mg AzithromycinTM once a day for an upper respiratory infection on December 13, 
2007 until December 17, 2007.  He was started on 800 mg-160 mg Bactrim DSTM once a 
day for urinary tract infection on January 11, 2008 until January 22, 2008.  He was 
started on 250 mg LevaquinTM once a day for urinary tract infection on January 22, 2008 
until January 30, 2008.  He was started on 100 mg MacrobidTM twice a day for urinary 
tract infection on February 7, 2008 until February 23, 2008.  He was started on 800 mg-
160 mg Bactrim DSTM once a day for urinary tract infection on February 29, 2008 until 
March 8, 2008.  He started on 800 mg-160 mg Bactrim DSTM once a day for urinary tract 
infection on March 10, 2008 until March 21, 2008. 
Nutrition Care Plan 
On December 4, 2007, Case Study One was at nutrition risk due to the following:  
weight loss, history of cancer, acute renal insufficiency, depression, infection, diagnosis 
of dehydration, and provided intravenous fluids, was on a mechanically altered soft diet, 
and had an alteration in nutritional laboratory values.  On May 5, 2007, Case Study One 
was at nutrition risk due to the following: weakness, poor appetite, decreased food 
intakes, congestive heart failure, renal insufficiency, patient reports history of 36 pound 
weight loss since November 2006, patient has history of prostate cancer, patient 
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complains of problems chewing and requests diet consistency be changed to soft 
consistency.  Patient is edentulous and only wears an upper denture.  On July 30, 2007, 
Case Study One was at nutritional risk due to the following: recent surgery, congestive 
heart failure, post ileus operation, and altered nutritional laboratory values.  Patient was 
edentulous with upper dentures, does not wear lower dentures due to poor fit, and 
declined a dental referral at this time.  
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Table 2.  Case Study One Bowel Movement Chart 
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Table 2 Continued.  Case Study One Bowel Movement Chart 
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Table 2 Continued.  Case Study One Bowel Movement Chart 
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Interpretation of Bowel Movement Chart for Case Study One 
 Case Study One started the first antibiotic which led to an influx of diarrhea while 
still on the antibiotic and continued for four days.  However, when the probiotic was 
started after those four days, Case Study One started having a more normalized bowel 
pattern.  The probiotic was continued and the second antibiotic was started, and this time 
instead of an increase in diarrhea, it was minimized.  The probiotic was continued when 
the next five antibiotics were started, and this time, there was not a notable change in 
stool consistency.  The only change while on the probiotic was with the eighth antibiotic 
and it was only for one day.  Case Study One was on the bowel movement protocol 
during the course of antibiotics and analysis of the probiotic effectiveness.  
Case Study Two  
A white female, born on September 12, 1923, was admitted to the long-term care 
facility on September 20, 2006 and discharged on October 11, 2006. She was readmitted 
on November 26, 2008 until December 22, 2008.  
Bowel Movement Protocol 
Case Study Two was placed on the bowel movement protocol on September 21, 
2006 until October 11, 2006.  The bowel movement protocol was restarted on December 
8, 2008 until December 22, 2008.   
Probiotic Plan  
Case Study Two was administered one capsule per day of the probiotic, 
CulturelleTM, on December 8, 2008 until December 24, 2008. 
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Antibiotic Plan 
Case Study Two was placed on 500 mg KeflexTM twice a day for an unknown 
reason on September 20, 2006 until September 26, 2006.  She was started on 100 mg 
MacrobidTM twice a day for an unknown reason on September 20, 2006 until September 
26, 2006.  She was then started on 250 mg CiproTM twice a day for an unknown reason on 
December 6, 2008 until December 16, 2008.  She was also given 800 mg-160 mg 
Bactrim DSTM twice a day for an unknown reason on December 6, 2008 until December 
14, 2008.  
Nutrition Care Plan 
On September 25, 2006, Case Study Two was at nutritional risk due to the 
following: advanced age, recent compression fractures, osteoporosis, history of 
dysphagia, and patient is edentulous.  On December 1, 2008, Case Study Two was at 
nutritional risk due to the following: advanced age, dementia, weakness, and altered 
nutrition related laboratory values.  Patient has loose fitting dentures but declines a 
referral to the dentist.  
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Table 3.  Case Study Two Bowel Movement Chart. 
 
 
Interpretation of Bowel Movement Chart for Case Study Two 
Case Study Two did not show an obvious change in stool consistency when 
placed on the two antibiotics and probiotic.  She did have an increase in number of stools 
for one day after the first antibiotic was started.  Case Study Two was placed on the 
bowel movement protocol on the same day as the probiotic. 
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Case Study Three 
A white female, born on June 19, 1925, was admitted to the long-term care 
facility on March 25, 2003 and discharged April 10, 2003.  She was readmitted January 
9, 2007 and discharged February 1, 2007.  She was readmitted on February 9, 2008 until 
February 16, 2008. 
Bowel Movement Protocol 
Case Study Three was placed on the bowel movement protocol on January 9, 
2008 until February 1, 2008.  The bowel movement protocol was restarted on February 8, 
2008 with no stop date. 
Probiotic Plan  
Case Study Three was administered one capsule per day of the probiotic, 
CulturelleTM, on February 10, 2008 with no stop date. 
Antibiotic Plan 
Case Study Three was placed on 500 mg LevaquinTM once a day for an unknown 
reason on March 26, 2003 until March 31 2003.  She was started on 500 mg DuncefTM 
twice a day for urinary tract infection on April 2, 2003 until April 3, 2003. She was 
started on 800 mg-160 mg Bactrim DSTM twice a day for an unknown reason on April 3, 
2003 until April 10, 2003. She was started on 500 mg FlagylTM three times a day for an 
unknown reason on January 9, 2008 until January 10, 2008.  She was started on 500 mg 
AmpicillinTM twice a day for an unknown reason on January 27, 2008 until January 31, 
2008.  
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Nutrition Care Plan 
On April 4, 2003, Case Study Three was at nutritional risk due to the following: 
leaving more than 25 percent at most meals, urinary tract infection, constipation, and 
abnormal nutrition laboratory values.  On January 11, 2008, Case Study Three was at 
nutritional risk due to the following: stroke, advanced age, history of gastrointestinal 
bleed, dementia, and needs total assistance with meals.  On February 6, 2008, Case Study 
Three was at nutritional risk due to the following: stroke, gastrointestinal bleeding, food 
intakes of less than 50 percent, insufficient fluid intake, advanced age, altered nutritional 
laboratory values, needs total assistance with meals, leucocytosis, hypernatremia, stage 
one wound on buttock, dementia, and hypertension. 
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Table 4.  Case Study Three Bowel Movement Chart.  
 
Interpretation of Bowel Movement Chart for Case Study Three 
Case Study Three did not have a noticeable change in stool consistency when 
placed on two antibiotics.  However, Case Study Three had a bout of diarrhea at the end 
of taking both antibiotics that did not clear up until being administered the probiotic for 
three days.  Case Study Three was on the bowel movement protocol while on the 
probiotic. 
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Case Study Four  
A white male, born on September 12, 1925, was admitted to the long-term care 
facility on November 15, 2003 and discharged November 26, 2003.  He was readmitted 
on October 22, 2007 and discharged November 13, 2007.   He was readmitted on January 
26, 2007 until December 11, 2007. 
Bowel Movement Protocol 
Case Study Four was placed on the bowel movement protocol on November 18, 
2003 until November 26, 2003.  The bowel movement protocol was restarted on October 
23, 2007 until November 13, 2007. 
Probiotic Plan 
Case Study Four was administered one capsule per day of the probiotic, 
CulturelleTM, on November 28, 2007 until December 7, 2007. 
Antibiotic Plan 
  
Case Study Four was placed on 250 mg LevaquinTM once a day for an unknown 
reason on November 15, 2003 and stopped on the same day.  He was then started on 100 
mg MacrobidTM twice a day for an unknown reason on November 15, 2003 until 
November 26, 2003.  Next, he was started on 800 mg-160 mg Bactrim DSTM once a day 
for Methicillin-resistant Staphylococcus aureus (MRSA) in the urine on November 15, 
2003 until November 26, 2003. He was started on 800 mg-160 mg Bactrim DSTM twice a 
day for an unknown reason on November 26, 2007 until December 12, 2007.  
Nutrition Care Plan 
On October 24, 2007, Case Study Four was at nutrition risk due to the following: 
advance age, recent compression fracture, diabetes, hypertension, and altered nutritional 
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laboratory values.  On November 28, 2007, Case Study Four was at nutritional risk due to 
the following: advance age, undesirable underweight status, 87 percent ideal body 
weight, fair food intakes, compression fracture, urinary tract infection, diabetes, and 
altered skin integrity. 
Table 5.  Case Study Four Bowel Movement Chart.  
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Interpretation of Bowel Movement Chart for Case Study Four 
Case Study Four did not have a noticeable change in stool consistency or number 
of stools per day when placed on three antibiotics and the probiotic.  Case Study Four 
was placed on and stopped the bowel movement protocol before starting the antibiotics 
and probiotic. 
Case Study Five  
A white male, born on November 21, 1949, was admitted to a long-term care 
facility on May 23, 2002 and discharged February 3, 2008.  He was readmitted on 
February 8, 2008 until March 5, 2008.  
Bowel Movement Protocol 
Case Study Five was placed on the bowel movement protocol on February 21, 
2008 with no stop date. 
Probiotic Plan 
Case Study Five was administered one capsule per day of the probiotic, 
CulturelleTM, on February 13, 2008 until February 24, 2008.  
Antibiotic Plan 
Case Study Five was placed on 500 mg LevaquinTM once a day for an unknown 
infection on February 8, 2008 until February 17, 2008.  
Nutrition Care Plan 
On February 13, 2008, Case Study Five was at nutritional risk due to the 
following: dysphagia, urinary tract infection, dementia, and altered nutritional laboratory 
values. 
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Table 6.  Case Study Five Bowel Movement Chart.  
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Interpretation of Bowel Movement Chart for Case Study Five 
Case Study Five did not have a noticeable change in stool consistency or number 
of stools per day when placed on the antibiotic and the probiotic.  Case Study Five was 
placed on the bowel movement protocol while still on the probiotic.  It was continued 
after the probiotic was stopped, with no noticeable change in stools. 
Case Study Six  
A white female, born on March 25, 1914, was admitted to a long-term care 
facility on September 22, 2006 and discharged on October 4, 2006.  She was readmitted 
on September 4, 2008 and discharged September 26, 2008.  She was readmitted on 
November 3, 2008 and discharged November 24, 2008.  She was readmitted on 
November 28, 2008 until December 6, 2008. 
Bowel Movement Protocol  
Case Study Six was placed on the bowel movement protocol on September 25, 
2006 to October 4, 2006.  The bowel movement protocol was restarted on September 5, 
2008 to September 26, 2008.  Again the bowel movement protocol was started on 
November 4, 2008 until November 25, 2008. 
Probiotic Plan 
Case Study Six was administered one capsule per day of the probiotic, 
CulturelleTM, on September 6, 2008 to September 12, 2008.  She was re-administered the 
probiotic, CulturelleTM, once per day, November 17, 2008 to November 20, 2008.  She 
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was re-administered the probiotic, CulturelleTM, once per day, December 4, 2008 to 
January 7, 2009. 
Antibiotic Plan 
  
Case Study Six was placed on 250 mg FlagylTM four times a day for Clostridium 
difficile on September 4, 2008 until September 11, 2008. She was started on 250 mg 
CiproTM twice a day for an unknown reason on November 16, 2008 until November 23, 
2008.  She was started on 500 mg FlagylTM three times a day for Clostridium difficile on 
November 23, 2008 until December 3, 2008.  She was started again on 250 mg FlagylTM 
once a day for an unknown reason, November 28, 2008 until December 16, 2008.  Lastly 
she was started on 250 mg LevaquinTM once a day for an unknown reason on November 
28, 2008 until December 1, 2008.  
Nutrition Care Plan  
 
On September 26, 2006, Case Study Six was at nutritional risk due to the 
following: advanced age, congestive heart failure, diabetes, hypothyroidism, altered 
nutritional laboratory values, and recent endarterectomy.  On September 5, 2008, Case 
Study Six was at nutritional risk due to the following: advanced age, Clostridium difficile, 
recent pneumonia, diabetes, congestive heart failure, hypertension, dehydration, history 
thyroidectomy, cholycystectomy, and pressure area to right heel.  On November 6, 2008, 
Case Study Six was at nutritional risk due to the following: a history of stroke and 
Clostridium difficile, diabetes, peripheral neuropathy, congestive heart failure, 
hypertension, hypothyroidism, arthritis, urinary tract infection, renal insufficiency, 
advanced age, dentures, deep tissue wound, noted as a ³SLFN\HDWHU´ per nursing, recent 
weight loss, and requires assistance with meals. 
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Table 7.  Case Study Six Bowel Movement Chart  
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Interpretation of Bowel Movement Chart for Case Study Six 
Case Study Six had increase change in the number of stools after starting the first 
antibiotic, which was decreased when the probiotic was started.  The bowel movement 
protocol was stopped for a period of time and when it was restarted, the consistency 
changed and number of stools increased.  After two days, the stool became more 
regulated.  When the next antibiotic was started, there was a noticeable increase in 
consistency and number of stools.  The probiotic did not seem to moderate the stools.  
However, when another antibiotic was started, the probiotic had a noticeable increase in 
the number of stools.  Case Study Six was started on one antibiotic and probiotic that did 
not work.  She was also started on another antibiotic while on a probiotic that did work in 
normalizing the stools. 
Case Study Seven  
A white female, born on June 12, 1915, was admitted to the long-term care 
facility on November 4, 2005 and discharged November 18, 2005.  She was readmitted 
on February 19, 2007 and discharged on February 24, 2007.  She was readmitted on 
August 19, 2008 and discharged September 22, 2008.  She was readmitted in January 13, 
2009 with no discharge date.  
Bowel Movement Protocol 
Case Study Seven was place on the bowel movement protocol on November 4, 
2005 until November 18, 2005.  The bowel movement protocol was restarted on February 
19, 2007 until February 24, 2007.  The bowel movement protocol was restarted on 
August 20, 2008 until September 22, 2008.  
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Probiotic Plan 
Case Study Seven was administered one capsule per day of the probiotic, 
CulturelleTM, on August 2, 2008 until September 2, 2008.  She was re-administered one 
capsule per day of the probiotic, CulturelleTM, January 15, 2009 until January 30, 2009. 
She was re-administered one capsule per day of the probiotic, CulturelleTM, on February 
3, 2009 with no stop date. She was re-administered one capsule per day of the probiotic, 
CulturelleTM, March 18, 2009 with no stop date.    
Antibiotic Plan 
Case Study Seven was placed on 250 mg LevaquinTM once a day for an unknown 
reason on November 4, 2005 until November 11, 2005.  She was started on 250 mg 
LevaquinTM once a day for urinary tract infection on February 19, 2007 until March 1, 
2007.  She was started on 500 mg KeflexTM three times a day for an unknown reason on 
August 19, 2008 until August 27, 2008. She was started on 50 mg/1 ml solution 
VancomycinTM four times a day for an unknown reason on January 13, 2009 until 
January 23, 2009. She was started on 500 mg FlagylTM every six hours a day for an 
unknown reason January 13, 2009 until January 23, 2009. She was started on 50 mg/1 ml 
solution VancomycinTM four times a day for an unknown reason February 1, 2009 and 
stopped on the same day.  She was started on 125 mg VancomycinTM every six hours a 
day for an unknown reason on February 1, 2009 until February 10, 2009.  She was started 
on 500 mg FlagylTM every six hours a day for an unknown reason on February 1, 2009 
until February 10, 2009. She was started on 250 mg FlagylTM four a day for Clostridium 
difficile on February 19, 2009 until February 20, 2009. She was started on 250 mg 
FlagylTM once a day for Clostridium difficile on March 13, 2009 until March 30, 2009.  
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She was started on 125 mg VancomycinTM four times a day for Clostridium difficile on 
March 13, 2009 until March 30, 2009. She was started on 200 mg XifaxanTM three times 
a day for Clostridium difficile March 26, 2009 until April 5, 2009. She was started on 300 
mg RifampinTM twice a day for an unknown reason on April 24, 2009 until May 15, 
2009. She was started on 125 mg Vancomycin TM every six hours a day for an unknown 
reason on April 24, 2009 until May 6, 2009. She was started on 250 mg LevaquinTM once 
a day for urinary tract infection on June 15, 2009 and stopped the same day. She was 
started on 400 mg BactrimTM twice a day for an unknown reason on June 15, 2009 until 
June 20, 2009.  
Nutrition Care Plan 
On November 9, 2005, Case Study Seven was at nutrition risk due to the 
following: advanced age, pneumonia, congestive obstructive pulmonary disease, and 
anemia.  On February 23, 2007, Case Study Seven was at nutritional risk due to: 
advanced age, decreased food intakes, congestive heart failure, and pre-renal azotemia. 
Case Study Seven was admitted to the hospital with a small bowel obstruction but stated 
that she normally does not have problems with constipation.  On August 20, 2008, Case 
Study Seven was at nutritional risk due to the following: advanced age, hypothyroidism, 
hypertension, congestive obstructive pulmonary disease, urinary tract infection, and 
altered nutritional laboratory values.  On January 15, 2009, Case Study Seven was at 
nutritional risk due to the following: advanced age, Clostridium difficile, congestive heart 
failure, urinary tract infection, gastric esophageal reflux disease, stage two pressure areas 
to coccyx, and decreased food intakes.  
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Table 8.  Case Study Seven Bowel Movement Chart.  
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Interpretation of Bowel Movement Chart for Case Study Seven 
The first antibiotic that was started, did not seem to have a noticeable change 
since the probiotic was started at the same time.  However, when two other antibiotics 
were started, there was a huge increase in number of stools and change in consistency.  
Even though the probiotic was started, it did not decrease the number or the consistency 
of stools during the analysis period. 
Case Study Eight  
A white female, born on August 8, 1935, was admitted to the long-term care 
facility on December 20, 2006 and discharged February 27, 2007. She was readmitted on 
March 2, 2007 until April 2, 2007.  
Bowel Movement Protocol 
Case Study Eight was placed on the bowel movement protocol on December 22, 
2006 until February 27, 2007.  The bowel movement protocol was restarted on March 5, 
2007 with no stop date.   
Probiotic Plan 
Case Study Eight was administered one capsule per day of the probiotic, 
CulturelleTM, on March 11, 2007 with no stop date.  
Antibiotic Plan 
  Case Study Eight was started on 500 mg LevaquinTM once a day for an unknown 
reason on December 31, 2006 until January 30, 2007. She was started on 250 mg 
LevaquinTM once a day for an unknown reason on January 19, 2007 until January 30, 
2007. She was started on 500 mg CiproTM twice a day for an unknown reason on 
February 8, 2007 until February 14, 2007. She was started on 500 mg LevaquinTM once a 
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day for an unknown reason February 19, 2007 until February 27, 2007.  She was started 
on 500 mg LevaquinTM once a day for an unknown reason February 26, 2007 until March 
7, 2007.  She was started on 500 mg LevaquinTM once a day for an unknown reason 
March 9, 2007 until March 20, 2007.  She was started on 250 mg LevaquinTM once a day 
for an unknown reason March 22, 2007 until March 23, 2007.  
Nutrition Care Plan 
On December 22, 2006, Case Study Eight was at nutritional risk due to the 
following: dementia, left hip fracture, anemia, altered nutritional laboratory values, stage 
two pressure areas to left buttock and fair food intakes.  On March 11, 2007, Case Study 
Eight was at nutritional risk due to the following: dementia, right total knee replacement, 
recent left hip fracture, irritable bowel syndrome, urinary tract infection, and diarrhea. 
Clostridium difficile test came back negative on March 8, 2007. 
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Table 9.  Case Study Eight Bowel Movement Chart. 
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Interpretation of Bowel Movement Chart for Case Study Eight 
Case Study Eight stool consistency and number of stools were not noticeably 
affected by the first three antibiotics.  However, when the fourth antibiotic was started, 
the consistency and number increased.  Once the probiotic was started, the stools became 
more regulated for the final analyzed period. 
Case Study Nine  
A white female, born on April 17, 1914, was admitted to the long-term care 
facility on June 12, 2007 and discharged July 9, 2007.  She was readmitted on January 
10, 2008 until January 27, 2008.   
Bowel Movement Protocol 
Case Study Nine was placed on the bowel movement protocol on June 14, 2007 
until July 9, 2007.  The bowel movement protocol was restarted on January 15, 2008 until 
January 23, 2008.   
Probiotic Plan 
Case Study Nine was administered one capsule per day of the probiotic, 
CulturelleTM, on January 11, 2008 with no stop date.  
Antibiotic Plan 
Case Study Nine was started on 800 mg-160 mg BactrimTM DS twice a day for 
pneumonia June 20, 2007 until July 9, 2007.  She was started on 250 mg LevaquinTM 
once a day for an unknown reason July 3, 2007 until July 11, 2007.  She was started on 
875 mg-125 mg Amoxicillian-ClavulanteTM twice a day for pneumonia January 10, 2008 
until January 17, 2008. She was started on 500 mg ZithromaxTM once a day for 
pneumonia January 10, 2008 until January 14, 2008.   
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Nutrition Care Plan 
On June 14, 2007, Case Study Nine was at nutritional risk due to the following: 
failure to thrive diagnosis, dementia, hypertension, gastric esophageal reflux disease, and 
advanced age.  On January 11, 2008, Case Study Nine was at nutritional risk due to the 
following: poor food intakes, gastric esophageal reflux disease, aspiration precautions, 
advanced age, altered diet consistency, nectar fluids, stage two pressure sore, and 
required assistance with meals. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
44 
 
Table 10.  Case Study Nine Bowel Movement Chart.  
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Interpretation of Bowel Movement Chart for Case Study Nine 
 Case Study Nine was placed on the bowel movement protocol at the same time as 
being started on two antibiotics.  There was not a noticeable change in stool consistency 
or number of stools.  The bowel movement protocol was discontinued in July.  In January 
another antibiotic and probiotic were started.  The number of stools did not seem to 
increase, but the consistency changed and was soft even when the probiotic was 
administered.   
Case Study Ten 
A white male, born on April 16, 1930, was admitted to the long-term care facility 
on May 8, 2007 and discharged on May 27, 2007.  He was readmitted on May 29, 2007 
and discharged September 10, 2007.  He was readmitted on September 12, 2007 and 
discharged February 3, 2008.  He was readmitted on February 7, 2008 until June 19, 
2008.  
Bowel Movement Protocol 
Case Study Ten was placed on the bowel movement protocol on May 29, 2007 
until September 11, 2007.  The bowel movement protocol was restarted on September 12, 
2007 until January 13, 2008. The bowel movement protocol was restarted on February 
28, 2008 until April 30, 2008.  The bowel movement protocol was restarted May 1, 2008 
until May 28, 2008. 
Probiotic Plan 
Case Study Ten was administered two capsules per day of the probiotic, 
CulturelleTM, on May 24, 2007 until August 24, 2007.  He was re-administered one 
capsule per day of the probiotic, CulturelleTM on December 30, 2007 until February 4, 
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2008.  He was re-administered one capsule per day of the probiotic, CulturelleTM on May 
12, 2008 with no stop date. 
Antibiotic Plan 
Case Study Ten was started on 500 mg ZithromaxTM once a day for an unknown 
reason July 3, 2007 until July 6, 2007.  He was started on 800 mg-160 mg Bactrim DSTM 
twice a day for an unknown infection August 27, 2007 until August 28, 2007.   He was 
started on 800 mg-160 mg Bactrim DSTM twice a day for an unknown infection August 
27, 2008 until September 3, 2007.  He was started on 500 mg LevaquinTM once a day for 
an unknown reason October 6, 2007 until October 13, 2007.  He was started on 400 mg 
ZyvoxTM twice a day for an unknown reason December 13th, 2007 until December 23, 
2007.  He was started on 250 mg KeflexTM twice a day for unknown reason January 11, 
2008 until January 21, 2008. He was started on 800 mg-160 mg Bactrim DSTM twice a 
day for unknown reason February 17, 2008 until February 25, 2008.  He was started on 
750 mg LevaquinTM every 48 hours for unknown reasons February 26, 2008 until 
February 29, 2008.  He was started on 750 mg LevaquinTM every 48 hours for unknown 
reason February 26, 2008 until February 29, 2008.  He was started on 80 mg/400 mg 
Trimethoprim with sulfaTM twice a day for unknown infection February 26, 2008 until 
March 3, 2008.  He was started on 250 mg CiproTM twice a day for unknown infection 
March 3, 2008 until March 9, 2008.  
Nutrition Care Plan 
On May 10, 2007, Case Study Ten was at nutritional risk due to the following: 
stroke, aspiration pneumonia, history of hyponatremia, gastric esophageal reflux disease, 
esophageal dilution, and dysphagia secondary to stroke.  On August 8, 2007, Case Study 
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Ten was at nutritional risk due to the followingKLVWRU\RI&URKQ¶VGLVHDVHSDWLHQt 
FRQVLGHUHGD³SLFN\HDWHU´by the nursing staff, and currently dependant on tube feeding. 
On September 17, 2007, Case Study Ten was at nutritional risk due to the following: 
recent bowel obstruction, history of stroke with dysphagia, aspiration pneumonia, gastric 
esophageal reflux disease&URKQ¶VGLVHDVHZHLJKWORVVand poor food intakes. 
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Table 11.  Case Study Ten Bowel Movement Chart.  
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Interpretation of Bowel Movement Chart for Case Study Ten 
Case Study Ten was administered multiple antibiotics, bowel movement protocol, 
and probiotic.  There was not a noticeable change in consistency or number of stools 
when Case Study Ten was placed on the probiotic during the analyzed period.   
 
Case Study Eleven  
A white male, born on April 20, 1916, was admitted to the long-term care facility 
on November 5, 2004 and discharged March 1, 2006.  He was readmitted March 10, 2006 
and discharged November 10, 2008.  He was readmitted on November 10, 2008 with no 
discharge date.  
Bowel Movement Protocol 
Case Study Eleven was placed on the bowel movement protocol on November 5, 
2004 until January 11, 2006.  The bowel movement protocol was restarted on February 
16, 2006 until March 1, 2006.  The bowel movement protocol was restarted March 14, 
2006 until December 30, 2007.  The bowel movement protocol was restarted on January 
2, 2008 until November 8, 2008.  The bowel movement protocol was restarted on January 
31, 2009 with no stop date.  
Probiotic Plan 
Case Study Eleven was administered one capsule per day of the probiotic, 
CulturelleTM, on March 17, 2008 with no stop date.  He was re-administered one capsule 
per day of the probiotic, CulturelleTM on April 4, 2008 until April 12, 2008.  He was re-
administered one capsule per day of the probiotic, CulturelleTM on June 11, 2008 with no 
stop date.  He was re-administered one capsule per day of the probiotic, CulturelleTM on 
October 28, 2008 with no stop date. 
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Antibiotic Plan 
Case Study Eleven was started on TRI-PakTM once a day for an unknown reason 
November 9, 2004 until November 12, 2004.  He was started on 100 mg Macrobid twice 
per day for an unknown reason November 20, 2004 until November 28, 2004.  He was 
started on 875 mg AmoxicillinTM twice a day for an unknown reason November 29, 2004 
until December 8, 2004.  He was started on 400 mg AveloxTM once a day for another 
unknown reason December 26, 2007 until December 30, 2007.  He was started on 500 
mg LevaquinTM once a day for pneumonia December 31, 2007 until January 8, 2008.  He 
was started on 500 mg LevaquinTM once a day for an unknown reason March 13, 2008 
until March 16, 2008.  He was started on 750 mg LevaquinTM once a day for pneumonia 
March 17, 2008 until March 21, 2008.  He was started on 750 mg LevaquinTM once a day 
for an unknown reason April 1, 2008 until April 7, 2008.  He was started on 500 mg 
LevaquinTM once a day for upper respiratory infection July 6, 2008 until August 13, 
2008. He was started on 500 mg LevaquinTM once a day for an unknown reason 
November 6, 2008 until November 8, 2008.  
Nutrition Care Plan 
On November 28, 2005, Case Study Eleven was at nutritional risk due to the 
following: partial dependence on tube feeding for macronutrient and hydration needs, 
history of weight loss, history of pressure ulcers, edentulous, history of constipation, 
altered nutritional laboratory values, advanced age, nausea, and vomiting.  
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Table 12.  Case Study Eleven Bowel Movement Chart.  
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Interpretation of Bowel Movement Chart for Case Study Eleven 
Case Study Eleven was placed on the bowel movement protocol before being 
placed on antibiotics and probiotic.  Once the antibiotics and probiotic were started, there 
was no noticeably change in consistency and number of stools.  
Case Study Twelve  
A white male, born on August 30, 1918, was admitted to the long-term care 
facility on October 10, 2008 and discharged October 22, 2008.  He was readmitted on 
November 19, 2008 and discharged November 20, 2008.  He was readmitted on 
December 1, 2008 and discharged December 24, 2008.  He was readmitted December 27, 
2008 and discharged January 14, 2009.  He was readmitted January 27, 2009 until 
February 21, 2009.  
Bowel Movement Protocol 
Case Study Twelve was placed on the bowel movement protocol on December 
20, 2007 until February 1, 2008.  The bowel movement protocol was restarted on October 
10, 2008 until October 31, 2008.  The bowel movement protocol was restarted on 
December 9, 2008 until December 26, 2008. The bowel movement protocol was restarted 
on January 7, 2009 until January 14, 2009.  The bowel movement protocol was restarted 
on February 2, 2009 with no stop date.  
Probiotic Plan 
Case Study Twelve was administered two capsules per day of the probiotic, 
CulturelleTM, on October 16, 2008 until October 26, 2008.  He was administered two 
capsules per day of the probiotic, CulturelleTM, December 1, 2008 until December 26, 
2008. 
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Antibiotic Plan  
Case Study Twelve was started on 750 mg LevaquinTM once a day for pneumonia 
October 10, 2008 until October 13, 2008.  He was started on 1000 mg/10 ml intravenous 
fluid VancomycinTM once a day for an unknown infection December 1, 2008 until 
December 11, 2008.  
Nutrition Care Plan 
On December 27, 2007, Case Study Twelve was at nutritional risk due to the 
following: advanced age, a recent right hip fracture, chronic constipation, hypertension, 
and altered nutritional laboratory values.  On October 16, 2008, Case Study Twelve was 
at nutritional risk due to the following: advanced age, pressure sores, fractured scapula, 
pneumonia, loose stools, and altered nutritional laboratory values.  On December 6, 2008, 
Case Study Twelve was at nutritional risk due to the following: advanced age, altered diet 
consistency thickened due to aspiration, pneumonia, Methicillin-resistant Staphylococcus 
aureus (MRSA) plus sputum, and history of bladder cancer.  On January 3, 2009, Case 
Study Twelve was at nutritional risk due to the following: advanced age, weakness, 
Methicillin-resistant Staphylococcus aureus (MRSA), sepsis, and altered nutrition 
laboratory values. 
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Table 13.  Case Study Twelve Bowel Movement Chart.  
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Interpretation of Bowel Movement Chart for Case Study Twelve 
Case Study Twelve was started on an antibiotic which changed the consistency 
and number of stools until the probiotic was started.  Once the probiotic was started, the 
consistency and number of stools was noticeably regulated.   
Case Study Thirteen 
A white female, born on May 12, 1919, was admitted to the long-term care 
facility on October 14, 2006 and discharged May 16, 2007. She was readmitted on May 
21, 2007 and discharged April 20, 2008.  She was readmitted on April 21, 2008 and 
discharged May 9, 2008.  She was readmitted on May 13, 2008 and discharged May 31, 
2008.   She was readmitted on June 9, 2008 with no discharge date.   
Bowel Movement Protocol 
Case Study Thirteen was placed on the bowel movement protocol on October 16, 
2006 until October 19, 2006.  The bowel movement protocol was restarted on April 20, 
2007 until April 25, 2007.  The bowel movement protocol was restarted on May 20, 2007 
until May 22, 2007.  The bowel movement protocol was restarted on August 6, 2007 until 
August 9, 2007. The bowel movement protocol was restarted on November 24, 2007 until 
April 10, 2008.  The bowel movement protocol was restarted on April 20, 2008 until 
April 22, 2008.  The bowel movement protocol was restarted on May 9, 2008 until May 
13, 2008.  The bowel movement protocol was restarted on June 1, 2008 with no stop date.   
Probiotic Plan 
Case Study Thirteen was administered one capsule per day of the probiotic, 
CulturelleTM on July 21, 2007 until August 2, 2007.  She was administered one capsule 
per day of the probiotic, CulturelleTM on December 28, 2007 until January 10, 2008.  She 
was administered one capsule per day of the probiotic, CulturelleTM on June 10, 2008 
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until July 1, 2008.  She was administered one capsule per day of the probiotic, 
CulturelleTM on September 9, 2008 until September 17, 2008.  She was administered one 
capsule per day of the probiotic, CulturelleTM on November 25, 2008 until December 3, 
2008.  She was administered one capsule per day of the probiotic, CulturelleTM on 
December 21, 2008 until December 29, 2008.  She was administered one capsule per day 
of the probiotic, CulturelleTM on July 1, 2009 until July 13, 2009.  She was administered 
one capsule per day of the probiotic, CulturelleTM on August 3, 2009 until August 16, 
2009.  
Antibiotic Plan 
Case Study Thirteen was started on 300 mg ClindamycinTM once a day for an 
unknown infection October 14, 2006 until October 19, 2006.  She was started on 300 mg 
CleocinTM three a day for an unknown infection November 3, 2006 until November 25, 
2006.  She was started on 300 mg ClindamycinTM once a day for an unknown infection 
March 13, 2007 until April 20, 2007.  She was started on 200 mg MacrobidTM twice a day 
for urinary tract infection April 23, 2007 until May 1, 2007.  She was started on 250 mg 
LevaquinTM once a day for pneumonia September 6, 2007 until September 7, 2007.  She 
was started on 500 mg Biaxin filmtabTM twice a day for pneumonia September 7, 2007 
and was stopped the same day.  She was started on 750 mg LevaquinTM once a day for an 
unknown reason September 7, 2007 until September 12, 2007.  She was started on 300 
mg ClindamycinTM four times a day for pneumonia November 24, 2007 until December 
5, 2007.  She was started on 500 mg LevaquinTM once a day for lower respiratory 
infection February 2, 2008 until February 26, 2008.  She was started on 500 mg 
LevaquinTM once a day for an unknown reason April 21, 2008 until April 26, 2008.  She 
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was started on 100 mg MacrobidTM twice a day for urinary tract infection April 23, 2008 
until May 1, 2008.  She was started on 500 mg LevaquinTM once a day for pneumonia 
May 14, 2008 until May 21, 2008.  She was started on 500 mg LevaquinTM once a day for 
an unknown reason June 9, 2008 until June 12, 2008.  She was started on 800 mg-160 mg 
Bactrim DSTM once a day for an unknown infection September 4, 2008 and stopped the 
same day.  She was started on 750 mg LevaquinTM once a day for an unknown reason 
September 4, 2008 until September 15, 2008.  She was started on 750 mg LevaquinTM 
once a day for an unknown reason December 17, 2008 until December 23, 2008.  She 
was started on 750 mg LevaquinTM once a day for an unknown reason June 30, 2009 until 
July 5, 2009.  She was started on 750 mg LevaquinTM once a day for an unknown reason 
August 2, 2009 until August 9, 2009.   
Nutrition Care Plan 
On January 11, 2008, Case Study Thirteen was at nutritional risk due to the 
following: advanced age, undesirable overweight status, diabetes, congestive heart 
failure, osteoporosis with history of vertebral fracture, anemia, hypertension, 
constipation, gastric esophageal reflux disease, hypothyroidism, and altered nutritional 
laboratory values.  On April 22, 2008, Case Study Thirteen was at nutritional risk due to 
the following: humoral fracture, frequent urinary tract infections, congestive heart failure, 
hypothyroidism, asthma, osteoporosis, hypertension, history of peptic ulcer, advanced 
age, altered nutritional laboratory values, dentures with mouth pain, altered diet 
consistency, and aspiration risk.  On May 16, 2008, Case Study Thirteen was at 
nutritional risk due to the following: high aspiration risk, peptic ulcer, chronic anemia, 
diabetes, hypothyroidism, humoral fracture, advanced age, altered nutritional laboratory 
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values, altered diet consistency, and loose upper denture.  On June 10, 2008, Case Study 
Thirteen was at nutritional risk due to the following: advanced age, congestive 
obstructive pulmonary disease, left humoral fracture, diabetes, osteoporosis, 
hypothyroidism, anemia, high aspiration risk, and upper dentures not fitting properly. 
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Table 14.  Case Study Thirteen Bowel Movement Chart.  
 
 
60 
 
Table 14 Continued.  Case StudyThirteen Bowel Movement Chart.  
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Table 14 Continued.  Case StudyThirteen Bowel Movement Chart.  
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Interpretation of Bowel Movement Chart for Case Study Thirteen 
 Case Study Thirteen was first started on a number of antibiotics followed by the 
bowel movement protocol and then the probiotics.  When the probiotic was administered, 
the antibiotic and bowel movement protocol were continued.  There was no noticeable 
change in stool consistency or number when the probiotic was started.   
Case Study Fourteen  
A white female, born on June 12, 1915, was admitted to the long-term care 
facility on May 3, 2007 and discharged December 22, 2007. 
Bowel Movement Protocol 
Case Study Fourteen was placed on the bowel movement protocol on May 4, 
2007 until October 31, 2007.  The bowel movement protocol was restarted on November 
13, 2007 until December 19, 2007.   
Probiotic Plan 
Case Study Fourteen was administered one capsule per day of the probiotic, 
CulturelleTM, from July 10, 2007 until July 25, 2007.  She was administered one capsule 
per day of the probiotic, CulturelleTM, as it was restarted on November 14, 2007 with no 
stop date. 
Antibiotic Plan  
Case Study Fourteen was started on 250 mg LevaquinTM once a day for an 
unknown reason July 5, 2007 until July 11, 2007.  She was started on 100 mg 
MacrobidTM once a day for an unknown infection July 7, 2007 until July 16, 2007.  She 
was started on 300 mg OmnicefTM twice a day for urinary tract infection November 12, 
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2007 until November 20, 2007.  She was started on 875 mg-125 mg AugmentinTM twice 
a day for urinary tract infection December 6, 2007 until December 13, 2007.  
Nutrition Care Plan 
On May 4, 2007, Case Study Fourteen was at nutritional risk due to the following: 
osteoporosis, hypothyroidism, dementia, urinary tract infection, pneumonia, depression, 
mild dehydration, hypercholesterolemia, altered nutritional laboratory values, poor food 
intakes, advanced age, and dentures.  On November 14, 2007, Case Study Fourteen was 
at nutritional risk due to the following: osteoporosis, recent fracture, hypothyroidism, 
dementia, urinary tract infection, depression, altered nutritional laboratory values, history 
of poor food intakes, advanced age, and dentures. 
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Table 15.  Case Study Fourteen Bowel Movement Chart.  
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Interpretation of Bowel Movement Chart for Case Study Fourteen 
Case Study Fourteen was started on the bowel movement protocol prior to starting 
antibiotics and probiotic.  There was not a noticeable change in the consistency and 
number of stools when the first two antibiotics were started since the probiotic was 
started at the same time.  When the next round of antibiotics and probiotic were started, 
the only noticeable change was a decrease in number of stools.  For the rest of the 
analyzed period, there was not a noticeable change in consistency. 
Case Study Fifteen 
 
A white male, July 12, 1919 on, was admitted to the long-term care facility on 
April 18, 2007 and discharged on May 3, 2007.   He was readmitted on February 18, 
2008 until March 5, 2008.  He was readmitted on June 24, 2008 until June 28, 2008.   
Bowel Movement Protocol 
Case Study Fifteen was placed on the bowel movement protocol on April 18, 
2007 until January 28, 2008.  He was restarted on the bowel movement protocol on June 
25, 2008 with no stop date. 
Probiotic Plan 
Case Study Fifteen was administered one capsule per day of the probiotic, 
CulturelleTM on February 22, 2008 until March 31, 2008.  He was administered one 
capsule per day of the probiotic, CulturelleTM on June 26, 2008 until July 3, 2008. 
Antibiotic Plan  
Case Study Fifteen was started on 500 mg LevaquinTM once a day for pneumonia 
February 18, 2008 with no stop date.  
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Nutrition Care Plan 
On May 2, 2007, Case Study Fifteen was at nutritional risk due to the following: 
history of recurrent pneumonia, congestive obstructive pulmonary disease, anemia, 
altered nutritional laboratory values, edema, and 76 percent of ideal body weight on 
admission to facility.  On February 22, 2008, Case Study Fifteen was at nutritional risk 
due to the following: chronic constipation, congestive obstructive pulmonary disease, 
dementia, chronic anemia, gastric esophageal reflux disease, stage two wound to coccyx, 
and infection.  On June 26, 2008, Case Study Fifteen was at nutritional risk due to the 
following: 81 percent ideal body weight, congestive obstructive pulmonary disease, 
pneumonia, dementia, altered nutritional laboratory values, thrush, decreased appetite and 
decreased food intakes. 
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Table 16.  Case Study Fifteen Bowel Movement Chart. 
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Table 16 Continued.  Case Study Fifteen Bowel Movement Chart. 
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Table 16 Continued.  Case Study Fifteen Bowel Movement Chart. 
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 Interpretation of Bowel Movement Chart for Case Study Fifteen 
Case Study Fifteen was started on an antibiotic which did not noticeably change 
the consistency and number of stools before and while the probiotic was administered.    
Case Study Sixteen  
A white male, born on August 3, 1933, was admitted to the long-term care facility 
on October 16, 2007 and discharged October 30, 2007.  He was readmitted November 5, 
2007 until December 7, 2007.  He was readmitted December 13, 2007 until January 12, 
2008.  He was readmitted May 15, 2008 until May 23, 2008.    
Bowel Movement Protocol 
Case Study Sixteen was placed on the bowel movement protocol on October, 17, 
2007 until October 30, 2007.  He was restarted on the bowel movement protocol on 
December 15, 2007 until January 12, 2008.  He was restarted on the bowel movement 
protocol on May 15, 2008 with no stop date. 
Probiotic Plan 
Case Study Sixteen was administered one capsule per day of the probiotic, 
CulturelleTM on November 5, 2007 until December 8, 2007.  He was administered one 
capsule per day of the probiotic, CulturelleTM on December 28, 2007 until January 10, 
2008.  He was administered one capsule per day of the probiotic, CulturelleTM on May 
16, 2008 until June 2, 2008. 
Antibiotic Plan  
Case Study Sixteen was started on 250 mg LevaquinTM once a day for urinary 
tract infection October 16, 2007 until October 24, 2007.  He was started on 875 mg 
AugmentinTM once a day for an infection November 5, 2007 until November 13, 2007.  
He was started on 100 mg MacrobidTM once a day for urinary tract infection November 
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13, 2007 until November 15, 2007.  He was started on 875 mg AmoxicillinTM twice a day 
for an unknown reason November 23, 2007 until December 1, 2007.  He was started on 
500 mg LevaquinTM once a day for an unknown reason December 4, 2007 until 
December 8, 2007.  He was started on 875 mg AugmentinTM twice a day for urinary tract 
infection December 11, 2007 until December 13, 2007.  He was started on 800 mg 
BactriumTM twice a day for an unknown reason December 31, 2007 until January 10, 
2008.  
Nutrition Care Plan 
On May 16, 2008, Case Study Sixteen was at nutritional risk due to the following: 
urinary tract infection, anemia, history of prostate cancer, history of colon cancer, and 
altered nutritional laboratory values. 
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Table 17.  Case Study Sixteen Bowel Movement Chart.  
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Interpretation of Bowel Movement Chart for Case Study Sixteen 
Case Study Sixteen was started on an antibiotic which did not noticeably change 
the consistency and number of stools before and while the probiotic was administered.    
Case Study Seventeen 
A white female, born on April 20, 1933, was admitted to the long-term care 
facility on January 11, 2008 and discharged on February 5, 2008.  She was readmitted on 
February 13, 2008 and discharged on March 3, 2008.  She was readmitted on July 26, 
2008 until on October 3, 2008. 
Bowel Movement Protocol 
Case Study Seventeen was placed on the bowel movement protocol on July 29, 
2008 with no stop date.  
Probiotic Plan 
Case Study Seventeen was administered one capsule per day of the probiotic, 
CulturelleTM, on February 22, 2008 with no stop date.  She was re-administered one 
capsule per day made into paste of the probiotic, CulturelleTM on August 18, 2008 with 
no stop date. 
Antibiotic Plan  
Case Study Seventeen was started on 100 mg DiflucanTM once a day for an 
unknown infection February 24, 2008 until March 2, 2008.  
Nutrition Care Plan 
On January 15, 2008, Case Study Seventeen was at nutritional risk due to the 
following: recent stroke, hypertension, diabetes, hyperlipidemia, and recent sacral 
fracture.  On February 22, 2008, Case Study Seventeen was at nutritional risk due to the 
following&XVKLQJ¶VSyndrome, urinary tract infection with fever, diabetes, 
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hyperlipidemia, obesity, history of stroke times two, sacral fracture, gastric esophageal 
reflux disease, altered nutritional laboratory values, very picky eater, and food intakes 
less than 75 percent.  On July 29, 2008, Case Study Seventeen was at nutritional risk due 
to the following: fracture to the right humerous bone, diabetes, and obesity. 
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Table 18.  Case Study Seventeen Bowel Movement Chart.  
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Interpretation of Bowel Movement Chart for Case Study Seventeen 
Case Study Seventeen was started on an antibiotic which changed the consistency 
and number of stools until the probiotic was started.  Once the probiotic was started, the 
consistency and number of stools was noticeably regulated.  The bowel movement 
protocol was started before the antibiotic and probiotic were started with no stop date. 
Case Study Eighteen  
A white female, born on July 18, 1918, was admitted to the long-term care facility 
on February 22, 2008 and discharged on March 10, 2008.  
Bowel Movement Protocol 
Case Study Eighteen was placed on the bowel movement protocol on February 
25, 2008 with no stop date.  
Probiotic Plan 
Case Study Eighteen was administered per day one capsule of the probiotic, 
CulturelleTM, on February 28, 2008 until March 4, 2008. 
Antibiotic Plan 
Case Study Eighteen was started on 500 mg LevaquinTM once a day for urinary 
tract infection February 22, 2008 until February 25, 2008.  
Nutrition Care Plan 
On February 28, 2008, Case Study Eighteen was at nutritional risk due to the 
following: advanced age, pneumonia, and altered nutritional laboratory values. 
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Table 19.  Case Study Eighteen Bowel Movement Chart.  
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Interpretation of Bowel Movement Chart for Case Study Eighteen 
Case Study Eighteen did not have any noticeable changes in consistency when she 
was started on the antibiotic, bowel movement protocol, and probiotic.  However, the 
number of stools decreased when she was started on the antibiotic, bowel movement 
protocol, and probiotic.   
Case Study Nineteen 
A white female, born on November 22, 1906, was admitted to the long-term care 
facility on March 6, 2008 and discharged on March 17, 2008.  She was readmitted on 
March 20, 2008 and discharged March 31, 2008.  She was readmitted on April 2, 2008 
and discharged April 10, 2008.  She was readmitted on April 15, 2008 until May 2, 2008.  
Bowel Movement Protocol 
Case Study Nineteen was placed on the bowel movement protocol on March 17, 
2008 with no stop date. 
Probiotic Plan 
Case Study Nineteen was administered one capsule per day of the probiotic, 
CulturelleTM on March 13, 2008 and stopped the same day.  She was re-administered one 
capsule per day of probiotic, CulturelleTM on March 24, 2008 until April 12, 2008.  She 
was re-administered again one capsule per day of the the probiotic, CulturelleTM on April 
13, 2008 until April 15, 2008. 
Antibiotic Plan  
Case Study Nineteen was started on 500 mg LevaquinTM once a day for 
pneumonia March 17, 2008 until March 18, 2008.  She was started on 250 mg 
LevaquinTM once a day for pneumonia March 20, 2008 until March 24, 2008.  She was 
restarted on 250 mg LevaquinTM once a day for pneumonia March 30, 2008 until March 
79 
 
31, 2008.  She was started on 500 mg AugmentinTM once a day for pneumonia April 2, 
2008 until April 9, 2008.  She was started on 250 mg LevaquinTM once a day for an 
unknown reason April 2, 2008 until April 9, 2008.   
Nutrition Care Plan 
On March 13, 2008, Case Study Nineteen was at nutritional risk due to the 
following: advanced age, recent decrease in appetite, infection (pneumonia), weakness, 
anemia, and congestive heart failure.  On March 24, 2008, Case Study Nineteen was at 
nutritional risk due to the following: advanced age, pneumonia, congestive heart failure, 
anemia, hypoalbuminemia, altered nutritional laboratory values, decreased appetite, and 
constipation.  On April 3, 2008, Case Study Nineteen was at nutritional risk due to the 
following: advanced age, unstable wound to the left lower shin, pneumonia, congestive 
heart failure, renal insufficiency, and anemia. 
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Table 20.  Case Study Nineteen Bowel Movement Chart.  
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Interpretation of Bowel Movement Chart for Case Study Nineteen 
Case Study Nineteen did not have any noticeable changes in consistency and 
number of stools when she was started on the antibiotic, bowel movement protocol, and 
probiotic.   
Case Study Twenty  
A white female, born on December 4, 1923, was admitted to the long-term care 
facility on March 27, 2007 and discharged on May 7, 2007.  She was readmitted on June 
20, 2008 and discharged August 4, 2008.  She was readmitted on August 8, 2008 until 
September 22, 2008.  
Bowel Movement Protocol 
Case Study Twenty was placed on the bowel movement protocol on March 28, 
2007 until May 20, 2007.  The bowel movement protocol was restarted on June 20, 2008 
until July 31, 2008.  
Probiotic Plan 
Case Study Twenty was administered one capsule per day of the probiotic, 
CulturelleTM, on March 28, 2007 with no stop date.  She was re-administered one capsule 
per day of the probiotic, CulturelleTM, on July 7, 2008 until July 16, 2008.  She was re-
administered again one capsule per day of the probiotic, CulturelleTM, on July 28, 2008 
until August 8, 2008.  She was re-administered one capsule per day of the probiotic, 
CulturelleTM, on August 11, 2008 until August 18, 2008.  
Antibiotic Plan  
Case Study Twenty was started on 100 mg MacrobidTM twice a day for urinary 
tract infection July 4, 2008 and stopped the same day.  She was started on 500 mg 
LevaquinTM once a day for an unknown infection August 8, 2008 until August 11, 2008.  
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She was started on 500 mg MetronidazoleTM three times a day for an unknown infection 
August 8, 2008 until August 11, 2008.  
Nutrition Care Plan 
On March 28, 2007, Case Study Twenty was at nutritional risk due to the 
following: advanced age, she leaves more than 25 percent at most meals, patient states 
about 20 pounds weight loss, recent pneumonia, bronchitis, hypertension, iron deficiency, 
anemia, congestive heart failure, osteoporosis, gastric esophageal reflux disease, acute 
renal failure, and hypothyroidism.  On June 23, 2008, Case Study Twenty was at 
nutritional risk due to the following: advanced age, right hip fracture, congestive heart 
failure, altered nutritional laboratory values, diverticulosis, and a history of 108 pounds 
weight loss 18 months ago.  Patient declines snacks and/or supplements at this time.  On 
August 11, 2008, Case Study Twenty was at nutritional risk due to the following: 
advanced age, diverticulitis of sigmoid colon, congestive heart failure, and frequent 
diarrhea for past several months. 
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Table 21.  Case Study Twenty Bowel Movement Chart.  
 
 
 
84 
 
Interpretation of Bowel Movement Chart for Case Study Twenty 
Case Study Twenty was started on the bowel movement protocol and antibiotic at 
the same time but did not show any noticeable change in consistency and number of 
stools.  When both were stopped, the probiotic was started and there was an increase in 
number of stools and change in consistency.  During the rest of the analyzed period, there 
was not the same increase that was shown when the antibiotic and bowel movement 
protocol stopped. Case Study Twenty is one of two cases that showed a negative affect 
when taking the probiotic. 
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Discussion 
From these data, the researcher expected to determine a protocol for dietitians to 
follow when they have patients suffering from antibiotic-associated diarrhea and are 
considering placing them on a probiotic.  Even though there were noticeable limitations 
to the study, the researcher was able to see a connection between the antibiotic used and 
the effectiveness of the probiotic.  These results are summarized in Table 22.  The 
following antibiotics were administered to one case study each: Omnicef TM, 
Azithromycin TM, Amoxicillian TM, Clindamycin TM, DucefTM, Metronidazole TM, 
Amoxicillian-Clavulante TM, Cleocin TM, Rifampin Cleocin TM, Biaxin filmtab TM, TRI-
PakTM  AmpicillinTM, Xifaxin TM, Zyvox TM, and Trimethoprim with sulfa TM.  Keflex TM 
and Augmentin TM were each administered to three case studies.  Cipro TM and Flagyl TM 
were each administed to four case studies.  MacrobidTM was administered to eight of the 
case studies.  Bactrim DS TM was administered to nine of the case studies.  Levaquin TM 
was administered to eighteen of the case studies.  
Antibiotics affect patients differently, especially when they are associated with 
their stool consistency and number of stools. Typically, antibiotics are used for patients 
suffering from an infection.  The data collected did not always state the reason for 
implementation of the antibiotics. 
The results of this study appeared to illustrate that for patients in a long-term care 
facility, probiotic may be useful in regulating stool consistency and number of stools 
(Table 23).  However, for eleven of the twenty patients their stools had a period where 
there was no noticeable effect with probiotic use.  Ten of the patients who were placed on 
probiotics had positive effects (either stool consistency became more regulated or number 
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of stools decreased).  Case Study Seven had success with the probiotic when on only one 
antibiotic, however, when multiple antibiotics were started, the probiotic could not 
regulate the stools.  Two of the patients who were placed on probiotics had negative 
effects on their stools (either stool consistency became less regulated or number of stools 
increased).  It was difficult to determine the effect of the probiotic due to the use of the 
bowel movement protocol and lack of dietary records.  Two case studies, ten percent, 
were diagnosed and treated for Clostridium difficile.   
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Table 22. Antibiotic and Effectiveness of Probiotic 
Case Study Case Study Antibiotics Effectiveness of Probiotic 
One 1. Levaquin TM 500 mg 
2. Flagyl TM 250 mg 
3. Levaquin TM 500 mg 
4. Levaquin TM 750 mg 
5. Levaquin TM 750 mg 
6. Azithromycin TM 500 mg 
7. Azithromycin TM 250mg 
8. Bactrim DS TM 800 mg/160 mg 
9. Levaquin TM 250 mg 
10. Macrobid TM 100 mg 
11. Bactrim DS TM 800 mg/160 mg 
12. Bactrim DS TM 800 mg/160 mg 
The probiotic was started 
after the first antibiotic and 
was continued while the 
second, third, fourth, fifth, 
sixth, seventh, eighth, ninth, 
tenth, eleventh, and twelfth 
antibiotic were started.  
When the third antibiotic 
was started, it was clear that 
the probiotic decreased the 
number of bowel 
movements and regulated 
the stool consistency.  
During the eleventh and 
twelfth antibiotic, there was 
an increase in number of 
bowel movements, but it 
was clear that the probiotic 
decreased the side effects 
from antibiotic use. 
Two 1. Keflex TM 500 mg 
2. Macrobid TM 100 mg 
3. Cipro TM 250 mg 
4. Bactrim DS TM 800 mg/160 mg 
The probiotic was started 
after all four of the 
antibiotics and did not show 
any noticeable change of 
stool consistency and 
number of bowel 
movements. 
Three 1. Levaquin TM 500 mg 
2. Duncef TM 500 mg 
3. Bactrim DS TM 800 mg/160 mg 
4. Flagyl TM 500 mg 
5. Ampicillin TM 500 mg 
After the fourth and fifth 
antibiotics were stopped, 
there was an increase in 
number of bowel 
movements and stool 
consistency.  Later, the 
probiotic was started and 
regulated the stools. 
Four 1. Levaquin TM 250 mg 
2. Macrobid TM 100 mg 
3. Bactrim DS TM 800 mg/160 mg 
4. Bactrim DS TM 800 mg/160 mg 
The probiotic was started 
after the first three 
antibiotics and continued 
during the fourth antibiotic.  
The probiotic did not show 
any noticeable change of 
stool consistency and 
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number of bowel 
movements. 
Five 1. Levaquin TM 500 mg The probiotic was started 
during the antibiotic plan 
and did not show any 
noticeable change of stool 
consistency and number of 
bowel movements. 
Six 1. Flagyl TM 250 mg 
2. Cipro TM 250 mg 
3. Flagyl TM 500 mg 
4. Flagyl TM 250 mg 
5. Levaquin TM 250 mg 
The probiotics were started 
throughout the antibiotic 
plans. The probiotic did not 
show any noticeable change 
of stool consistency and 
number of bowel 
movements. 
Seven 1. Levaquin TM 250 mg 
2. Levaquin TM 250 mg 
3. Keflex TM 500 mg 
4. Vancomycin TM 50 mg/1 ml 
5. Flagyl TM 500 mg 
6. Vancomycin TM 50 mg/ 1 ml 
7. Vancomycin TM 125 mg 
8. Flagyl TM 500 mg 
9. Flagyl TM 250 mg 
10. Flagyl TM 250 mg 
11. Xifaxan TM 200 mg 
12. Rifampin TM 300 mg 
13. Vancomycin TM 250 mg 
14. Levaquin TM 250 mg 
15. Bactrim TM 400 mg 
When the probiotic was 
started with only one 
antibiotic, the stool 
remained regular.  However, 
when the remaining 
antibiotics were started, the 
probiotic could not regulate 
the stool consistency or 
number of stools. 
Eight 1. Levaquin TM 500 mg 
2. Levaquin TM 250 mg 
3. Cipro TM 500 mg 
4. Levaquin TM 500 mg 
5. Levaquin TM 500 mg 
6. Levaquin TM 500 mg 
7. Levaquin TM 250 mg 
There were no issues with 
the first three antibiotics 
affecting the stools.  When 
the fourth antibiotic was 
started, the stool consistency 
and number of stools was 
increased.  When the 
probiotic was started, it 
regulated the stools. 
Nine 1. Bactrim DS TM 800 mg/160 mg 
2. Levaquin TM 250 mg 
3. Amoxicillian-Clavulante TM 875 
mg/125 mg 
4. Zithromax TM 500 mg 
Antibiotic one and two were 
started prior to the probiotic.  
There was not a noticeable 
change in stool consistency 
and number of stools.  
When the fourth antibiotic 
was started, the consistency 
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of stools increased, however 
the number of stools 
remained the same.  
Ten 1. Zithromax TM 500 mg 
2. Bactrim DS TM 800 mg/160 mg 
3. Bactrim DS TM 800 mg/160 mg 
4. LevaquinTM 500 mg 
5. Zyvox TM 400 mg 
6. Keflex TM 250 mg 
7. Bactrim DS TM 800 mg/160 mg 
8. Levaquin TM 750 mg 
9. Levaquin TM 750 mg 
10. Trimethoprim with sulfa TM 80 
mg/400 mg 
11. Cipro TM 250 mg 
The probiotic did not show 
any noticeable change in 
stool consistency when the 
antibiotics were 
administered.  However, the 
number of stools increased 
even when the probiotic was 
implemented. 
Eleven 1. TRI-Pak TM 
2. Macrobid TM 100 mg 
3. Amoxicillin TM 875 mg 
4. Avelox TM 400 mg 
5. Levaquin TM 500 mg 
6. Levaquin TM 500 mg 
7. Levaquin TM 750 mg 
8. Levaquin TM 750 mg 
9. Levaquin TM 500 mg 
10. Levaquin TM 500 mg 
The probiotic was started at 
the same time as the 
antibiotic and there was no 
noticeable change in stool 
consistency and number of 
stools. 
Twelve 1. Levaquin TM 750 mg 
2. Vancomycin TM intravenous fluid 
1000 mg/10 ml 
When the first antibiotic 
was started, the stool 
consistency and number of 
stools increased.  However, 
when the probiotic was 
started, the stool consistency 
and number of stools 
decreased.  The probiotic 
regulated the stools even 
when the second antibiotic 
was started. 
Thirteen 1. Clindamycin TM 300 mg 
2. Cleocin TM 300 mg 
3. Clindamycin TM 300 mg 
4. Macrobid TM 200 mg 
5. Levaquin TM 250 mg 
6. Biaxin filmtab TM 500 mg 
7. Levaquin TM 750 mg 
8. Clindamycin TM 300 mg 
9. Levaquin TM 500 mg 
10. Levaquin TM 500 mg 
The probiotic was started 
after the bowel movement 
protocol was implemented. 
There was no noticeable 
change in the stool 
consistency.  However, the 
number of stools increased 
but then decreased when the 
probiotic was started. 
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11. Macrobid TM 100 mg 
12. Levaquin TM 500 mg 
13. Levaquin TM 500 mg 
14. Bactrim DS 800 mg/160 mg 
15. Levaquin TM 750 mg 
16. Levaquin TM 750 mg 
17. Levaquin TM 750 mg 
18. Levaquin TM 750 mg 
19. Levaquin TM 750mg 
Fourteen 1. Levaquin TM 250 mg 
2. Macrobid TM 100 mg 
3. Omnicef TM 300 mg 
4. Augmentin TM 875 mg/125 mg 
The first two antibiotics and 
probiotic were started at the 
same time. There was no 
change in stool consistency 
and number of stools. When 
the third antibiotic was 
started, there was an 
increase in number of stools 
and consistency.  The 
probiotic was then started 
and it decreased the number 
of stools and regulated the 
consistency.  When the 
fourth antibiotic was started, 
the probiotic was already 
administered, so it 
noticeably regulated the 
stool. 
Fifteen 1. Levaquin TM 500 mg The probiotic did not show 
any noticeable change in 
stool consistency or number 
of stools.  
Sixteen 1. Levaquin TM 250 mg 
2. Augmentin TM 875 mg 
3. Macrobid TM 100 mg 
4. Amoxicillian TM 875 mg 
5. Levaquin TM 500 mg 
6. Augmentin TM 875 mg 
7. Bactrim DS TM 800 mg/160 mg 
The probiotic was started 
after the first two antibiotics 
were administered.  When 
the fourth antibiotic was 
started, there was a slight 
increase in number of stools.  
However, there was not a 
noticeable change in stool 
consistency or number of 
stools with the rest of the 
antibiotics.  
Seventeen 1. Diflucan TM 100 mg The probiotic was started 
before the antibiotic was 
administered.  The probiotic 
regulated stool consistency 
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and number of stools.  
Eighteen 1. Levaquin TM 500 mg The probiotic was not 
administered until three 
days after the antibiotic plan 
was ended.  There was an 
increase in the number of 
stools that decreased after 
the probiotic was started.  
However, the stool 
consistency never changed. 
Nineteen 1. Levaquin TM 500 mg 
2. Levaquin TM 250 mg 
3. Levaquin TM 250 mg 
4. Augmentin TM 500 mg 
5. Levaquin TM 250 mg 
The probiotic was started 
before the antibiotics were 
administered. There was not 
a noticeable change in stool 
consistency or number of 
stools.  
Twenty 1. Macrobid TM 100 mg 
2. Levaquin TM 500 mg 
3. Metronidazole 500 mg 
When the antibiotic and 
bowel movement protocol 
were stopped, the probiotic 
was started and the number 
of stools increased. 
However, there was no 
noted increase for the rest of 
the analyzed time.  
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Table 23.  Summary of Effect of the Probiotic Plan  
 Effect of the Probiotic Plan  
Case Study One The probiotic may have caused a noticeable 
change in stool consistency and the number 
of stools after being implemented. (+) 
Case Study Two The probiotic did not show any noticeable 
change in stool consistency. (0) 
Case Study Three After three days of taking the probiotic, the 
stool consistency started to normalize. (+) 
Case Study Four The probiotic did not show any noticeable 
change in stool consistency. (0) 
Case Study Five The probiotic did not show any noticeable 
change in stool consistency. (0) 
Case Study Six The probiotic may have caused a noticeable 
change in stool consistency and the number 
of stools after being implemented. (+) 
Case Study Seven When the probiotic was started with only 
one antibiotic, the stool was able to remain 
regular.  However, when multiple 
antibiotics were started, the probiotic could 
not regulate the stools.(+/-) 
Case Study Eight There were no stool changes with the first 
three antibiotics.  When the fourth 
antibiotic was started, the stool consistency 
and number of stools increased.  When the 
probiotic was started, it regulated the 
stools. (+) 
Case Study Nine The probiotic regulated the consistency but 
there was not a noticeable change in 
number of stools. (+/0) 
Case Study Ten The probiotic did not show any noticeable 
change in stool consistency or number of 
stools. (0) 
Case Study Eleven The probiotic was started at the same time 
as the antibiotic and there was no 
noticeable change in stools. (0)  
Case Study Twelve The probiotic regulated the consistency and 
decreased the number of stools. (+) 
Case Study Thirteen The probiotic was started after the bowel 
movement protocol was implemented. 
There was no noticeable change in the 
stools once the probiotic was started. (0) 
Case Study Fourteen The first time antibiotics and probiotic were 
started at the same time. There was no 
93 
 
change. When the next antibiotic and 
probiotic were started, there was a decrease 
in number of stools. (0/+) 
Case Study Fifteen The probiotic did not show any noticeable 
change in stool consistency or number of 
stools. (0) 
Case Study Sixteen The probiotic did not show any noticeable 
change in stool consistency or number of 
stools. (0) 
Case Study Seventeen The probiotic regulated stool consistency 
and number of stools. (+) 
Case Study Eighteen The probiotic was not administered until 
three days after the antibiotic plan was 
ended.  There was an increase in the 
number of stools that decreased after the 
probiotic was started.  However, the stool 
consistency never changed. (+/0) 
Case Study Nineteen The probiotic did not show any noticeable 
change in stool consistency or number of 
stools. (0) 
Case Study Twenty When the antibiotic and bowel movement 
protocol were stopped, the probiotic was 
started and the number of stools increased. 
However, there was no noted increase for 
the rest of the analyzed time. (-) 
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Chapter V. Limitations 
Since the study was retrospective and this long-term care facility did not 
document the SDWLHQW¶V daily diet, there was not an accurate way to determine what the 
patient consumed.  Aspects of the diet, such as fiber intake, could also affect the stool 
number, quantity and consistency.  It would be important to know if the patient was 
eating higher fat food items that could cause gastrointestinal distress.  
In addition to providing patients with a probiotic, patients were on a bowel 
movement protocol which provided added fiber.  This protocol could mask the effect of 
the probiotic. It is difficult to determine the probiotic effect if the patient was given 
numerous stool softeners, antibiotics, as well as being on the probiotic at the same time.  
It is also difficult to separate the effects of each of those treatments to narrow the cause of 
the change in stool consistency and the increase in stool number. 
Another limitation is how the stools were scored.  The stools were assessed based 
on the judgment of the nursing staff and can be noted as inconsistent.  For example, in 
RQHSDWLHQW¶VERZHOUHFRUG, their stool from one bowel movement was listed as hard, 
diarrhea, soft, formed, and loose.  Stools were scored and included time, but the nursing 
staff gets busy and may not always document every stool correctly. 
Antibiotics affect patients differently, especially when it is associated with their 
stool consistency and number of stools. Typically, antibiotics are used for patients 
suffering from an infection.  Also, antibiotics may interact differently DQGHIIHFWSDWLHQWV¶
stool consistency and number of stools when a probiotic is present.  There may be a drug-
drug interaction between the antibiotic and probiotic.  With the numerous antibiotics 
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given we were not able to determine how the antibiotic and probiotic interacted. Aslos, 
the data collected did not always state the reason for implementation of the antibiotics.    
In most cases, patients were administered one capsule per day of the probiotic, 
CulturelleTM.  However, some patients were administered two capsules per day of 
probiotic, CulturelleTM. The Culturelle manufacturer recommends that an adult take one 
capsule per day of the probiotic (Amerifit Brand, 2010). 
Chapter VI. Future Trials and Recommendations 
Probiotics may play a beneficial role in several medical conditions including 
antibiotic-associated diarrhea.  Probiotics should be further investigated for their possible 
benefits to patients affected with antibiotic-associated diarrhea.  At the same time, the 
negative effects should be researched.  The combination and concentration of 
gastrointestinal microflora are determined and affected by a number of independent 
variables. Based on the results of this study, it is recommended that a protocol be set for 
use and research of probiotics in the elderly population.  
It is recommended that a more controlled study be conducted with elderly patients 
suffering from antibiotic-associated diarrhea and using probiotics to regulate the 
consistency and decrease the number of stools.  The controlled study would take into 
account the following recommendations.  It is important to note that ethical 
considerations should be taken into account and quality of life should be considered when 
conducting the controlled study.  First, the nursing staff should be taught how to correctly 
determine the stool consistency and be reminded of the importance of accurate 
documentation.  If the nursing staff learns a standardized method to score the stools, it 
will lead to more consistent stool data.  One example of how to score stool consistency is 
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found in Table 24.  This table provides pictures as well as the weight of stools.  In a 
controlled study, the stool data would be more accurate.  Fecal containment devices can 
allow staff to accurately measure the amount of the stool. 
7DEOH.LQJ¶V6WRRO&KDUW 
 
.LQJ¶V&ROOHJH/RQGRQ 
 
A background oIDSDWLHQWV¶W\SLFDOERZHOSDWWHUQLVXVHIXOZKHQWU\LQJWR
determine changes ZKHQSODFHGRQWKHSURELRWLF+DYLQJDEDFNJURXQGRIWKHSDWLHQW¶V
typical stool pattern would allow for a baseline.  Not everyone has a stool everyday 
compared to another patient who has three or four stools per day.  If the patient bowel 
history is collected prior to the implementation, it could potentially decrease the use of 
medication when not necessary.  
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3DWLHQWV¶GLHWDU\LQWDNH should be recorded; a dietary intake which includes the 
number of grams of fiber, grams of protein, grams of carbohydrate, and grams of fat.  
:LWKWKLVUHFRUGRIWKHSDWLHQW¶VGLHWDOLVWof any food allergies or intolerances, such as 
lactose intolerance, should be noted.  Another aspect of diet that needs to be recorded is 
the amount of fluid the patient is consuming.  Hydration will influence the stool 
consistency and number of bowel movements.  When the study is conducted, the patient 
should be on a controlled diet, to control for the dietary affects on the stool consistency 
and number of bowel movements.   
If a patient is on multiple regimens, such as bowel movement protocols and 
probiotics, then they should be excluded from the study.  By excluding those patients 
who are on multiple regimens of the bowel movement protocol, it may be difficult to 
maintain a large study size especially since the patients¶ quality of life needs to be 
maintained.  Or if patients on the bowel movement protocol are included in the study, it is 
important to control for the bowel movement protocol and have adequate information 
recorded (dates and times for administering the specific drug).  AOORIWKHSDWLHQWV¶
medications should be documented accurately, including time and dosage of antibiotics 
and stool softeners.  
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Chapter VIII. Conclusions 
Published studies for patients in long-term facilities vary greatly in terms of trial 
design, type and dose of probiotic and duration of treatment, which may explain why 
probiotics work for some patients and not for others.  Probiotic use is becoming more 
accepted with antibiotic-associated diarrhea but due to the lack of definitive evidence 
about efficacy and the safety of probiotic use, more studies need to be conducted. 
Overall, our research findings have shown that probiotics may have a positive 
effect on patients suffering from antibiotic-associated diarrhea. Due to the number of 
limitations, this project can be considered a pilot study for future more controlled studies 
to determine the effectiveness of the use of probiotics in elderly patients suffering from 
antibiotic-associated diarrhea.   
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Appendix A.  IRB Approval Letter 
April 5, 2010  
 
Jenna Peate 
Department of Nutrition and Health Sciences 
6400 White Dove Cir Lincoln, NE 68512  
 
Julie Albrecht 
Department of Nutrition and Health Sciences 
119 LEV, UNL, 68583-0806  
 
IRB Number: 2009049724 EP  
Project ID: 9724 
Project Title: Probiotic Use in Elderly 
 
Dear Jenna: 
 
7KLVLVWRRIILFLDOO\QRWLI\\RXRIWKHDSSURYDORI\RXUSURMHFW¶V&RQWLQXLQJ5HYLHZE\WKH
Institutional Review BoarGIRUWKH3URWHFWLRQRI+XPDQ6XEMHFWV,WLVWKHFRPPLWWHH¶VRSLQLRQ
that you have provided adequate safeguards for the rights and welfare of the subjects in this study 
based on the information provided. Your proposal is in compliance with DHHS Regulations for 
the Protection of Human Subjects (45 CFR 46). 
 
We wish to remind you that the principal investigator is responsible for reporting to this Board 
any of the following events within 48 hours of the event: 
* Any serious event (including on-site and off-site adverse events, injuries, side effects, deaths, or 
other problems) which in the opinion of the local investigator was unanticipated, involved risk to 
subjects or others, and was possibly related to the research procedures; 
* Any serious accidental or unintentional change to the IRB-approved protocol that involves risk 
or has the potential to recur; 
* Any publication in the literature, safety monitoring report, interim result or other finding that 
indicates an unexpected change to the risk/benefit ratio of the research; 
* Any breach in confidentiality or compromise in data privacy related to the subject or others; or 
* Any complaint of a subject that indicates an unanticipated risk or that cannot be resolved by the 
research staff. 
 
It is the responsibility of the principal investigator to provide the Board with a review and update 
of the research project each year the project is in effect. This approval is valid until 04/22/2011. 
 
If you have any questions, please contact the IRB office at 472-6965. 
 
Sincerely, 
Becky R. Freeman, CIP  
for the IRB 
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Appendix B.  Bowel Movement Protocol 
 
The purpose of the bowel movement plan or protocol is to ensure regularity and 
prevention of impaction.  At the facility, each patient is assessed to determine if he/she 
has regular bowel movements.  If not, a plan for bowel care was initiated in a timely 
manner ensuring that the client remains free of constipation and impaction.  The 
procedure starts with resident assistants documenting patients¶ bowel movements each 
shift for their assigned client and recording it in Care TrackerTM.  Next, the staff observes 
cognitively impaired patients for behaviors that could indicate the need to evacuate 
bowels, such as restlessness, digging in the rectum, and agitation.  These behaviors were 
reported to the charge nurse for follow up.  Next, the evening shift nurse or medication 
DLGHUXQVD³ERZHOPRYHPHQWSURWRFROFURVVWDE´Ueport in Care TrackerTM to identify the 
total number of days each patient has not had a bowel movement.  Also, if the patient 
does not have bowel care orders or a problem has been identified, the charge nurse will 
QRWLI\WKHSK\VLFLDQRIWKHSDWLHQWV¶ERZHOVWDWXVDQGUHTXHVWDQRUGHUIRUXVHRIfacility 
bowel care pURWRFRORURWKHURUGHUVWRPDQDJHSDWLHQWV¶ERZHOVDs per physician order.  
The bowel care protocol starts at 4 pm on day three of no bowel movement at which time, 
30 ml Milk of MagnesiaTM is given.  At 4 pm on day four of no bowel movement, 10 mg 
Suppository R Bisacodyl (DulcolaxTM) is given.  If no stool occurs within 4 hours of 
having DulcolaxTM, the patient is re-evaluated to rule out impaction and administered one 
of the following: Enema R of Sodium Phosphate (fleets) or 4oz Magnesium Citrate.  If no 
UHVXOWVWKHSK\VLFLDQLVXSGDWHGRQWKHSDWLHQWV¶ERwel status, at which time a request for 
routine bowel medication may be made.  The nurse will update the care plan and inform 
the staff of the pUREOHPQHHGUHJDUGLQJWKHSDWLHQWV¶ bowel movement and the 
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interventions for those patients who require bowel care programs.  The nurse will follow 
up to ensure that the patLHQWV¶ERZHOFDUHSODQZDVHIIHFWLYH7KHSDWLHQWV¶QXWULWion and 
hydration status is assessed on admission and on an ongoing basis by the Food and 
Nutrition Department of the facility. 
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Appendix C.  Probiotic Protocol 
 
Purpose of the probiotic plan is to prevent/minimize diarrhea and diarrhea 
associated complications in immune compromised individuals. Upon admission to 
facility, patients receiving antibiotic therapy will receive probiotic therapy to positively 
influence the microflora of the colon, decreasing toxic microbial activities. The long term 
care facility defines immune compromised individuals as those who have a reduced 
resistance to illness (elderly, chronic illness).  The long term care facility defines 
probiotics as a live mircrobial feed supplement that beneficially affects the host by 
improving its microbial balance.  Probiotics exert their benefits through several 
mechanisms; they prevent colonization, cellular adhesion and invasion by pathogenic 
organisms, they have a direct antimicrobial activity and they modulate the host immune 
response. The long term care facility defines prebiotics as nourishment for probiotic 
bacteria to aid in faster growth of good bacteria.  The probiotic is implemented when in 
certain situations.  One situation is when a patient is admitted with recent, less than two 
weeks or frequent antibiotic use.  Another situation is when a patient or resident is 
currently receiving an antibiotic.  Finally, if a patient has diarrhea from an unknown 
etiology the probiotic will be initiated. There is a procedure that is followed for the 
implementation of the probiotic.  The registered dietitian will initiate the probiotic after 
evaluation of the medical chart and patient assessment.  The probiotic will be written in 
the medication report to be given one capsule per day, unless otherwise indicated.  The 
dietitian will then add it to the nutrition care plan for the patient.  The probiotic will be 
given for seven days following discontinuation of the antibiotic or until stools have been 
documented normal for seven consecutive days.  The dietitian may recommend the 
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probiotic use indefinitely if the patient has chronic altered bowel movement pattern or is 
immunocompromised.  The dietitian will be notified by the nursing staff when a probiotic 
is initiated.  The long term care facility follows a set of instructions for the use of the 
probiotic.  The dosage is one capsule per day of the probiotic unless the dietitian states 
otherwise.  The long term care facility has approved using the probiotic, CulturelleTM.  
 
